var title_f33_60_34752="Stool sample 1 with answer";
var content_f33_60_34752=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F53646&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F53646&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hookworm ovum in stool",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A wet mount of stool (x400) shows an ovum of hookworm. The eggs of the two species of hookworm, Necator americanus and Ancylostoma duodenale, are indistinguishable in wet mounts.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_60_34752=[""].join("\n");
var outline_f33_60_34752=null;
var title_f33_60_34753="Pleural effusion CT";
var content_f33_60_34753=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F86361&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F86361&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Computed tomography: Left-sided pneumonia with pleural effusion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 377px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dwight A Powell, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_60_34753=[""].join("\n");
var outline_f33_60_34753=null;
var title_f33_60_34754="Management of chronic epicondylitis algorithm";
var content_f33_60_34754=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F69505&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F69505&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 576px\">",
"   <div class=\"ttl\">",
"    Management of chronic epicondylitis algorithm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 556px; height: 795px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     MRI: magnetic resonance imaging; PRP: platelet-rich plasma; U/S: ultrasound.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_60_34754=[""].join("\n");
var outline_f33_60_34754=null;
var title_f33_60_34755="Cisatracurium: Patient drug information";
var content_f33_60_34755=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Cisatracurium: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/1/26646?source=see_link\">",
"     see \"Cisatracurium: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?43/29/44501?source=see_link\">",
"     see \"Cisatracurium: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F152161\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Nimbex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F152162\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Nimbex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10021740\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10021742\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to calm muscles during surgery.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691273",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to calm muscles while on a breathing machine.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10021741\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701814",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to cisatracurium or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to benzyl alcohol, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10021745\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10021746\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698088",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flushing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698250",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Muscle weakness may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10021748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10021744\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10021749\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10021750\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12364 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-1A4E1675F2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_60_34755=[""].join("\n");
var outline_f33_60_34755=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152161\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152162\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021740\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021742\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021741\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021745\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021746\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021748\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021744\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021749\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021750\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?26/1/26646?source=related_link\">",
"      Cisatracurium: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?43/29/44501?source=related_link\">",
"      Cisatracurium: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_60_34756="Tolcapone: Patient drug information";
var content_f33_60_34756=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Tolcapone: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/47/33526?source=see_link\">",
"     see \"Tolcapone: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F228999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Tasmar&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10028371\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700728",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause liver problems. Blood tests will be needed to watch for any liver problems. They will be done before you start taking this drug and every 2 weeks during care. If you had liver changes from this drug in the past, do not use this drug again. Signs of liver problems include dark urine, feeling tired, not hungry, upset stomach, throwing up, or yellowing of the skin or eyes. Call your doctor right away if you have any of these signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10028373\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692011",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat Parkinson's disease.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10028372\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703048",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to tolcapone or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701308",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking monoamine oxidase inhibitors (eg, isocarboxazid, phenelzine, and tranylcypromine) talk with your doctor. Taking both at the same time could cause risky high blood pressure.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10028377\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698528",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking a blood thinner, have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10028378\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698040",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Extra muscle action or slow movement. Levodopa/carbidopa dose may need to be changed.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698201",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the liver may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10028380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10028375\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698545",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a diary of your signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10028376\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10028381\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10028382\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11102 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-189.41.181.191-9843F0D5B8-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_60_34756=[""].join("\n");
var outline_f33_60_34756=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228999\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028371\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028373\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028372\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028377\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028378\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028380\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028375\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028376\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028381\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028382\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?32/47/33526?source=related_link\">",
"      Tolcapone: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_60_34757="X-ray insufficiency fracture of the pubic ramus";
var content_f33_60_34757=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F85969&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F85969&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 532px\">",
"   <div class=\"ttl\">",
"    X-ray insufficiency fracture of the pubic ramus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 512px; height: 518px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The plain x-ray of the pelvis is from a 95-year-old male who sustained minimal trauma and complained of left groin pain. Image A is magnified in B and reveals a nondisplaced fracture of the superior pubic ramus (green arrow). A left inferior pubic ramus fracture is seen with difficulty in (C), and magnified and highlighted in D (red arrow). These findings are consistent with insufficiency fractures of the superior and inferior pubic rami.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Gregory Waryasz, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_60_34757=[""].join("\n");
var outline_f33_60_34757=null;
var title_f33_60_34758="Bupivacaine: Drug information";
var content_f33_60_34758=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Bupivacaine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?0/51/820?source=see_link\">",
"    see \"Bupivacaine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/17/43285?source=see_link\">",
"    see \"Bupivacaine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708636\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F142923\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Bupivacaine Spinal;",
"     </li>",
"     <li>",
"      Marcaine&reg;;",
"     </li>",
"     <li>",
"      Marcaine&reg; Spinal;",
"     </li>",
"     <li>",
"      Sensorcaine&reg;;",
"     </li>",
"     <li>",
"      Sensorcaine&reg;-MPF;",
"     </li>",
"     <li>",
"      Sensorcaine&reg;-MPF Spinal",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F142924\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Marcaine&reg;;",
"     </li>",
"     <li>",
"      Sensorcaine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F142962\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Local Anesthetic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F142927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Dose varies with procedure, depth of anesthesia, vascularity of tissues, duration of anesthesia, and condition of patient. Do not use solutions containing preservatives for caudal or epidural block.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Local anesthesia: Infiltration:",
"     </b>",
"     0.25% infiltrated locally; maximum: 175 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Caudal block",
"     </b>",
"     (preservative free): 15-30 mL of 0.25% or 0.5%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Epidural block",
"     </b>",
"     (other than caudal block; preservative free): Administer in 3-5 mL increments, allowing sufficient time to detect toxic manifestations of inadvertent I.V. or I.T. administration: 10-20 mL of 0.25% or 0.5%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Surgical procedures requiring a high degree of muscle relaxation and prolonged effects",
"     <b>",
"      only",
"     </b>",
"     : 10-20 mL of 0.75% (",
"     <b>",
"      Note:",
"     </b>",
"     Not to be used in obstetrical cases)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Peripheral nerve block:",
"     </b>",
"     5 mL of 0.25% or 0.5%; maximum: 400 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Sympathetic nerve block:",
"     </b>",
"     20-50 mL of 0.25%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Retrobulbar anesthesia:",
"     </b>",
"     2-4 mL of 0.75%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Spinal anesthesia:",
"     </b>",
"     Preservative free solution of 0.75% bupivacaine in 8.25% dextrose:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lower extremity and perineal procedures: 1 mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lower abdominal procedures: 1.6 mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Normal vaginal delivery: 0.8 mL (higher doses may be required in some patients)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cesarean section: 1-1.4 mL",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F142943\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/17/43285?source=see_link\">",
"      see \"Bupivacaine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Dose varies with procedure, depth of anesthesia, vascularity of tissues, duration of anesthesia, and condition of patient. Do not use solutions containing preservatives for caudal or epidural block.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Caudal block, epidural block, local anesthesia:",
"     </b>",
"     Children &gt;12 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Peripheral or sympathetic nerve block:",
"     </b>",
"     Children &gt;12 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Retrobulbar anesthesia:",
"     </b>",
"     Children &gt;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F142928\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15682358\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustments provided in manufacturer&rsquo;s labeling; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15682359\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustments provided in manufacturer&rsquo;s labeling; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F142906\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride: 0.25% [2.5 mg/mL] (20 mL, 50 mL); 0.5% [5 mg/mL] (20 mL, 50 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Marcaine&reg;: 0.5% [5 mg/mL] (50 mL) [contains methylparaben]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sensorcaine&reg;: 0.25% [2.5 mg/mL] (50 mL); 0.5% [5 mg/mL] (50 mL) [contains methylparaben]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride [preservative free]: 0.25% [2.5 mg/mL] (10 mL, 20 mL, 30 mL); 0.5% [5 mg/mL] (10 mL, 20 mL, 30 mL); 0.75% [7.5 mg/mL] (10 mL, 30 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Marcaine&reg;: 0.25% [2.5 mg/mL] (10 mL, 30 mL, 50 mL); 0.5% [5 mg/mL] (10 mL, 30 mL); 0.75% [7.5 mg/mL] (10 mL, 30 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sensorcaine&reg;-MPF: 0.25% [2.5 mg/mL] (10 mL, 30 mL); 0.5% [5 mg/mL] (10 mL, 30 mL); 0.75% [7.5 mg/mL] (10 mL, 30 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, premixed in D",
"     <sub>",
"      8.25",
"     </sub>",
"     W, as hydrochloride [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bupivacaine Spinal: 0.75% [7.5 mg/mL] (2 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Marcaine&reg; Spinal: 0.75% [7.5 mg/mL] (2 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sensorcaine&reg;-MPF Spinal: 0.75% [7.5 mg/mL] (2 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F142891\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F142908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Solutions containing preservatives should not be used for epidural or caudal blocks.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F142968\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Buprenorphine, clonidine, clonidine with morphine, fentanyl, fentanyl with ketamine, hydromorphone, ketamine, iohexol, morphine, sufentanil.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Clonidine with fentanyl, sodium bicarbonate.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F142907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Local or regional anesthesia; spinal anesthesia; diagnostic and therapeutic procedures; obstetrical procedures (only 0.25% and 0.5% concentrations)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     0.25%: Local infiltration, peripheral nerve block, sympathetic block, caudal or epidural block",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     0.5%: Peripheral nerve block, caudal and epidural block",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     0.75%",
"     <b>",
"      (not for obstetrical anesthesia)",
"     </b>",
"     : Retrobulbar block, epidural block.",
"     <b>",
"      Note:",
"     </b>",
"     Reserve for surgical procedures where a high degree of muscle relaxation and prolonged effect are necessary",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F142970\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Bupivacaine may be confused with mepivacaine, ropivacaine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Marcaine&reg; may be confused with Narcan&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication (epidural administration) among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F142960\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Incidence of adverse reactions is difficult to define. Most effects are dose related, and are often due to accelerated absorption from the injection site, unintentional intravascular injection, or slow metabolic degradation. The development of any central nervous system symptoms may be an early indication of more significant toxicity (seizure).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Cardiovascular: Hypotension, bradycardia, palpitation, heart block, ventricular arrhythmia, cardiac arrest",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Restlessness, anxiety, dizziness, seizure (0.1%); rare symptoms (usually associated with unintentional subarachnoid injection during high spinal anesthesia) include persistent anesthesia, paresthesia, paralysis, headache, septic meningitis, and cranial nerve palsies",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Nausea, vomiting; rare symptoms (usually associated with unintentional subarachnoid injection during high spinal anesthesia) include fecal incontinence and loss of sphincter control",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Rare symptoms (usually associated with unintentional subarachnoid injection during high spinal anesthesia) include urinary incontinence, loss of perineal sensation, and loss of sexual function",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Chondrolysis (continuous intra-articular administration), weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, pupillary constriction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Apnea, hypoventilation (usually associated with unintentional subarachnoid injection during high spinal anesthesia)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reactions (urticaria, pruritus, angioedema), anaphylactoid reactions",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F142911\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to bupivacaine hydrochloride, amide-type local anesthetics, or any component of the formulation; obstetrical paracervical block anesthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Use as intravenous regional anesthesia (Bier block) is considered contraindicated per accepted clinical practice.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F142895\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular effects: Bupivacaine-containing products have been associated with rare occurrences of arrhythmias, cardiac arrest, and death.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Intra-articular infusion related chondrolysis: Continuous intra-articular infusion of local anesthetics after arthroscopic or other surgical procedures is",
"     <b>",
"      not",
"     </b>",
"     an approved use; chondrolysis (primarily shoulder joint) has occurred following infusion, with some requiring arthroplasty or shoulder replacement.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory arrest: Local anesthetics have been associated with rare occurrences of sudden respiratory arrest, especially when administered near the head or neck.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizures: Convulsions due to systemic toxicity leading to cardiac arrest have also been reported, presumably following unintentional intravascular injection or administration near the head or neck.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease including patients with hypotension or heart block.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Acutely ill patients: Use with caution in acutely ill patients; dose reduction may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Debilitated patients: Use with caution in debilitated patients; dose reduction may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; dose reduction may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Obstetrical anesthesia:",
"     <b>",
"      [U.S. Boxed Warning]: The 0.75% concentration is not recommended for obstetrical epidural anesthesia; cardiac arrest with difficult resuscitation or death has occurred.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Preservative-containing solutions:",
"     <b>",
"      Do not use solutions containing preservatives for caudal or epidural block.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Administration: Intravascular injections should be avoided; aspiration should be performed prior to administration; the needle must be repositioned until no return of blood can be elicited by aspiration; however, absence of blood in the syringe does not guarantee that intravascular injection has been avoided. Intravenous regional anesthesia (Bier block) is not recommended; cardiac arrest and death have occurred with this method of administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Test dose: A test dose is recommended prior to epidural administration (prior to initial dose) and all reinforcing doses with continuous catheter technique.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Trained personnel: Clinicians using local anesthetic agents should be well trained in diagnosis and management of emergencies that may arise from the use of these agents. Resuscitative equipment, oxygen, and other resuscitative drugs should be available for immediate use.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F142957\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP2C19 (minor), CYP2D6 (minor), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F142900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May increase the serum concentration of Bupivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: May enhance the adverse/toxic effect of Local Anesthetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F142902\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2233562\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Decreased pup survival and embryocidal effects were observed in animal studies. Bupivacaine is approved for use at term in obstetrical anesthesia or analgesia.",
"     <b>",
"      [U.S. Boxed Warning]: The 0.75% is not recommended for obstetrical anesthesia.",
"     </b>",
"     Bupivacaine 0.75% solutions have been associated with cardiac arrest following epidural anesthesia in obstetrical patients and use of this concentration is not recommended for this purpose. Use in obstetrical paracervical block anesthesia is contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F142930\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Bupivacaine HCl (PF) Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25% (30 mL): $4.31",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5% (20 mL): $4.14",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Bupivacaine HCl Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25% (50 mL): $3.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5% (50 mL): $2.83",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.75% (30 mL): $3.19",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Marcaine Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25% (50 mL): $6.22",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5% (50 mL): $5.04",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.75% (10 mL): $3.86",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Marcaine Preservative Free Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25% (10 mL): $3.49",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5% (10 mL): $4.08",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Marcaine Spinal Intrathecal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.75-8.25% (2 mL): $4.54",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Sensorcaine Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25% (50 mL): $12.07",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5% (50 mL): $13.44",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Sensorcaine-MPF Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25% (30 mL): $8.29",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5% (30 mL): $6.19",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.75% (30 mL): $7.91",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Sensorcaine-MPF Spinal Intrathecal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.75-8.25% (2 mL): $4.72",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F142904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Vital signs, state of consciousness; signs of CNS toxicity",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038543\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Anekain (HR);",
"     </li>",
"     <li>",
"      Bucain (DE, HU);",
"     </li>",
"     <li>",
"      Bucaine (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Bunascan Spinal (ID);",
"     </li>",
"     <li>",
"      Bupicaina (AR);",
"     </li>",
"     <li>",
"      Bupine (PK);",
"     </li>",
"     <li>",
"      Bupinest S.P. (PE);",
"     </li>",
"     <li>",
"      Bupinex (PY, UY);",
"     </li>",
"     <li>",
"      Bupivacain Jenapharm (DE);",
"     </li>",
"     <li>",
"      Bupivacain-RPR (DE);",
"     </li>",
"     <li>",
"      Bupivacain-RPR CO!2 (DE);",
"     </li>",
"     <li>",
"      Bupivacaine Aguettant (FR);",
"     </li>",
"     <li>",
"      Bupivacaine B. Braun (FR);",
"     </li>",
"     <li>",
"      Buvacaina (EC);",
"     </li>",
"     <li>",
"      Buvacainas (CO);",
"     </li>",
"     <li>",
"      Buvanest Spinal (ID);",
"     </li>",
"     <li>",
"      Carbostesin (AT, CH, DE);",
"     </li>",
"     <li>",
"      Chirocaina (VE);",
"     </li>",
"     <li>",
"      Chlorhydrate de Bupivacaine Dakota (FR);",
"     </li>",
"     <li>",
"      Dolanaest (DE);",
"     </li>",
"     <li>",
"      Duracaine (CN);",
"     </li>",
"     <li>",
"      Kamacaine (IL);",
"     </li>",
"     <li>",
"      Macaine (ZA);",
"     </li>",
"     <li>",
"      Marcain (AU, DK, FI, GB, HN, HU, ID, IE, IT, JP, MY, NO, NZ, PT, RU, SE, SG);",
"     </li>",
"     <li>",
"      Marcaina (BR, GT, SV);",
"     </li>",
"     <li>",
"      Marcaine (AE, BE, BG, BH, CY, CZ, EE, EG, FR, GR, HK, IL, IQ, IR, JO, KP, KW, LB, LU, LY, NL, OM, PH, PL, QA, SA, SY, TH, TR, TW, YE);",
"     </li>",
"     <li>",
"      Marcaine Heavy (KP);",
"     </li>",
"     <li>",
"      Marcaine Plain (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Picain (FI);",
"     </li>",
"     <li>",
"      Recain (ID);",
"     </li>",
"     <li>",
"      Senpivac (PH);",
"     </li>",
"     <li>",
"      Sensorcaine (IN, PH);",
"     </li>",
"     <li>",
"      Svedocain (ES)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F142894\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blocks both the initiation and conduction of nerve impulses by decreasing the neuronal membrane's permeability to sodium ions, which results in inhibition of depolarization with resultant blockade of conduction",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F142910\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Anesthesia (route and dose dependent): 1-17 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration (route and dose dependent): 2-9 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~95%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic; forms metabolite (pipecoloxylidine [PPX])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination (age dependent): Neonates: 8.1 hours; Adults: 2.7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: Caudal, epidural, or peripheral nerve block: 30-45 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (~6% unchanged)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Dix SK, Rosner GF, Nayar M, et al, &ldquo;Intractable Cardiac Arrest Due to Lidocaine Toxicity Successfully Resuscitated With Lipid Emulsion,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2011, 39(4):872-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/60/34758/abstract-text/21263316/pubmed\" id=\"21263316\" target=\"_blank\">",
"        21263316",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Foxall G, McCahon R, Lamb J, et al, &ldquo;Levobupivacaine-Induced Seizures and Cardiovascular Collapse Treated With Intralipid,&rdquo;",
"      <i>",
"       Anaesthesia",
"      </i>",
"      , 2007, 62(5):516-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/60/34758/abstract-text/17448066/pubmed\" id=\"17448066\" target=\"_blank\">",
"        17448066",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lehmann LJ and Pallares VS, &ldquo;Subdural Injection of a Local Anesthetic With Steroids: Complication of Epidural Anesthesia,&rdquo;",
"      <i>",
"       South Med J",
"      </i>",
"      , 1995, 88(4):467-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/60/34758/abstract-text/7716603/pubmed\" id=\"7716603\" target=\"_blank\">",
"        7716603",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Litz RJ, Popp M, Stehr SN, et al, &ldquo;Successful Resuscitation of a Patient With Ropivacaine-Induced Asystole After Axillary Plexus Block Using Lipid Infusion,&rdquo;",
"      <i>",
"       Anaesthesia",
"      </i>",
"      , 2006, 61(8):800-1.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/60/34758/abstract-text/16867094/pubmed\" id=\"16867094\" target=\"_blank\">",
"        16867094",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Long WB, Rosenblum S, and Grady IP, &ldquo;Successful Resuscitation of Bupivacaine-Induced Cardiac Arrest Using Cardiopulmonary Bypass,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 1989, 69(3):403-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/60/34758/abstract-text/2774240/pubmed\" id=\"2774240\" target=\"_blank\">",
"        2774240",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mirtallo JM, Dasta JF, Kleinschmidt KC, et al, &ldquo;State of the Art Review: Intravenous Fat Emulsions: Current Applications, Safety Profile, and Clinical Implications,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2010, 44(4):688-700.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/60/34758/abstract-text/20332339/pubmed\" id=\"20332339\" target=\"_blank\">",
"        20332339",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Moore PA and Hersh EV, \"Local Anesthetics: Pharmacology and Toxicity,\"",
"      <i>",
"       Dent Clin North Am",
"      </i>",
"      , 2010, 54(4):587-99.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/60/34758/abstract-text/20831923/pubmed\" id=\"20831923\" target=\"_blank\">",
"        20831923",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Neal JM, Mulroy MF, and Weinberg GL, &ldquo;American Society of Regional Anesthesia and Pain Medicine Checklist for Managing Local Anesthetic Systemic Toxicity: 2012 Version,&rdquo;",
"      <i>",
"       Reg Anesth Pain Med",
"      </i>",
"      , 2012, 37(1):16-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/60/34758/abstract-text/22189574/pubmed\" id=\"22189574\" target=\"_blank\">",
"        22189574",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rosenblatt MA, Abel M, Fischer GW, et al, &ldquo;Successful Use of a 20% Lipid Emulsion to Resuscitate a Patient After a Presumed Bupivacaine-Related Cardiac Arrest,&rdquo;",
"      <i>",
"       Anesthesiology",
"      </i>",
"      , 2006, 105(1):217-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/60/34758/abstract-text/16810015/pubmed\" id=\"16810015\" target=\"_blank\">",
"        16810015",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Scott DB, Lee A, Fagan D, et al, &ldquo;Acute Toxicity of Ropivacaine Compared With That of Bupivacaine,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 1989, 69(5):563-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/60/34758/abstract-text/2679230/pubmed\" id=\"2679230\" target=\"_blank\">",
"        2679230",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sun KO, &ldquo;Convulsion Following Spinal Anaesthesia,&rdquo;",
"      <i>",
"       Anaesth Intensive Care",
"      </i>",
"      , 1995, 23(4):520-1.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/60/34758/abstract-text/7485961/pubmed\" id=\"7485961\" target=\"_blank\">",
"        7485961",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tuominen MK, Pere P, and Rosenberg PH, &ldquo;Unintentional Arterial Catheterization and Bupivacaine Toxicity Associated With Continuous Interscalene Brachial Plexus Block,&rdquo;",
"      <i>",
"       Anesthesiology",
"      </i>",
"      , 1991, 75(2):356-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/60/34758/abstract-text/1859023/pubmed\" id=\"1859023\" target=\"_blank\">",
"        1859023",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9169 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-14.112.150.12-587BC34546-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_60_34758=[""].join("\n");
var outline_f33_60_34758=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708636\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142923\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142924\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142962\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142927\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142943\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142928\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682358\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682359\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142906\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142891\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142908\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142968\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142907\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142970\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142960\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142911\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142895\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142957\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142900\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142902\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2233562\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142930\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323027\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142904\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038543\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142894\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142910\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9169\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9169|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?0/51/820?source=related_link\">",
"      Bupivacaine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/17/43285?source=related_link\">",
"      Bupivacaine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_60_34759="Embryology of kidney";
var content_f33_60_34759=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F53054&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F53054&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 578px\">",
"   <div class=\"ttl\">",
"    Embryology of the kidney",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 558px; height: 408px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Relationship of the intermediate mesoderm of the pronephric, mesonephric, and metanephric systems. In cervical and upper thoracic regions intermediate mesoderm is segmented; in lower thoracic, lumbar, and sacral regions it forms a solid, unsegmented mass of tissue, the nephrogenic cord. Note the longitudinal collecting duct, formed initially by the pronephros but later by the mesonephros. B) Excretory tubules of the pronephric and mesonephric systems in a 5-week-old embryo.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Sadler, T, PhD. Langman's Medical Embryology, Ninth Edition Image Bank. Baltimore: Lippincott Williams &amp; Wilkins, 2003. Copyright &copy;2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_60_34759=[""].join("\n");
var outline_f33_60_34759=null;
var title_f33_60_34760="Alopecia areata PI";
var content_f33_60_34760=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F50613&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F50613&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Alopecia areata",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 431px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    People with alopecia areata lose hair in splotches rather than in a predictable pattern.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_60_34760=[""].join("\n");
var outline_f33_60_34760=null;
var title_f33_60_34761="Ocular rosacea";
var content_f33_60_34761=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Ocular rosacea",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/60/34761/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/60/34761/contributors\">",
"     Anthony Bron, FRCOphth, FMedSci",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/60/34761/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/60/34761/contributors\">",
"     Mark V Dahl, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/60/34761/contributors\">",
"     Jonathan Trobe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/60/34761/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/60/34761/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/60/34761/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H27345122\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rosacea is a common and chronic disorder that is divided into four main subtypes based upon clinical manifestations. Ocular rosacea refers to disease that involves the eyelids and anterior globe. Erythematotelangiectatic, papulopustular, and phymatous rosacea are subtypes that affect the facial skin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34761/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The inflammatory, vascular, and glandular abnormalities that occur in ocular rosacea can result in blepharitis (inflammation of the eyelid margin), conjunctival hyperemia, dry eyes, ocular discomfort, or rosacea-associated keratitis. Although most patients with ocular rosacea present with concomitant cutaneous lesions, ocular involvement is the initial manifestation of this disease in a minority of patients.",
"   </p>",
"   <p>",
"    The clinical features, diagnosis, and treatment of ocular rosacea will be discussed here. Cutaneous rosacea is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/46/36584?source=see_link\">",
"     \"Rosacea: Pathogenesis, clinical features, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/24/29066?source=see_link\">",
"     \"Management of rosacea\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8274783\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Similar to cutaneous rosacea, ocular rosacea primarily affects adults, but the disorder may occasionally occur in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34761/abstract/3-9\">",
"     3-9",
"    </a>",
"    ]. In a retrospective study of 131 affected patients, the average age at presentation was 56 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34761/abstract/8\">",
"     8",
"    </a>",
"    ]. Unlike cutaneous rosacea, which exhibits a strong female predominance, the sex distribution of ocular rosacea is fairly even [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34761/abstract/10-13\">",
"     10-13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/46/36584?source=see_link&amp;anchor=H394012123#H394012123\">",
"     \"Rosacea: Pathogenesis, clinical features, and diagnosis\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The estimated risk for ocular disease among patients with cutaneous rosacea has varied widely, with reported prevalence rates ranging from less than 10 percent to more than 50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34761/abstract/7,9,11,14,15\">",
"     7,9,11,14,15",
"    </a>",
"    ]. Evidence is insufficient to conclude whether specific features of cutaneous rosacea are associated with increased likelihood for the development of ocular disease. However, some authors have proposed that ocular involvement may be more likely to occur in patients with a propensity for flushing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34761/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ocular rosacea may also occur in the absence of detectable cutaneous disease, although the nonspecific nature of the ocular symptoms makes the recognition of a rosaceal basis more difficult when skin involvement is not apparent. In one series of 99 patients with both cutaneous and ocular manifestations, ocular disease preceded cutaneous lesions in 20 percent, occurred concomitantly in 27 percent, and followed the development of cutaneous lesions in 53 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34761/abstract/7\">",
"     7",
"    </a>",
"    ]. Up to 30 years could elapse between the onset of cutaneous and ocular symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H73542216\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Innate immunologic factors, external insults, and vascular dysfunction have been proposed as potential contributors to the development of rosacea. However, the pathways that lead to the development of rosacea remain poorly understood, and few studies have explored the specific mechanisms that contribute to ocular manifestations. General theories on the pathogenesis of rosacea are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/46/36584?source=see_link&amp;anchor=H394012131#H394012131\">",
"     \"Rosacea: Pathogenesis, clinical features, and diagnosis\", section on 'Pathogenesis'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Based upon available data, the following factors may play a role in ocular involvement:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Upregulation of",
"       <span class=\"nowrap\">",
"        cytokines/matrix",
"       </span>",
"       metalloproteinases",
"      </strong>",
"      &ndash; Increased levels of interleukin-1&alpha; (IL-1&alpha;), a proinflammatory cytokine, and matrix metalloproteinase-9 (MMP-9), a degradative enzyme that may be stimulated by IL-1&alpha;, have been detected in tear fluid from patients with ocular rosacea [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/60/34761/abstract/16-18\">",
"       16-18",
"      </a>",
"      ]. Upregulation of MMP-9 may promote damage to the ocular tissues, thereby contributing to the signs and symptoms of ocular rosacea. The observation that",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      , a treatment commonly used in ocular rosacea, reduced the activity of MMP-9 in an in vitro study supports the possibility that MMP-9 may have a pathogenic role [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/60/34761/abstract/19\">",
"       19",
"      </a>",
"      ]. However, additional studies are necessary to validate this theory.",
"     </li>",
"     <li>",
"      <strong>",
"       Bacterial action",
"      </strong>",
"      &ndash; The increase in bacterial lid flora detected in rosacea blepharitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/60/34761/abstract/20\">",
"       20",
"      </a>",
"      ] and the response of ocular rosacea to antibacterial therapy suggest that such flora on the eyelids may be a stimulatory factor for ocular rosacea. One theory suggests that the action of bacterial lipases on the lipid secretion of the meibomian glands could lead to the release of toxic free fatty acids and glycerides that contribute to the blepharitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/60/34761/abstract/21,22\">",
"       21,22",
"      </a>",
"      ]. In concert with this theory, treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/10/3240?source=see_link\">",
"       minocycline",
"      </a>",
"      (an antibiotic commonly used in the treatment of ocular rosacea) has reduced eyelid flora in patients with ocular rosacea and has decreased free fatty acids and diglycerides in meibomian gland secretions from patients with rosacea-associated meibomianitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/60/34761/abstract/23,24\">",
"       23,24",
"      </a>",
"      ]. Tear film stability has also improved in patients with meibomian gland dysfunction following treatment with this agent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/60/34761/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Demodex",
"      </strong>",
"      &ndash;",
"      <em>",
"       Demodex",
"      </em>",
"      mites are common inhabitants of human skin in adolescents and adults, including the follicles of the eyelashes. As with cutaneous disease, the role of",
"      <em>",
"       Demodex",
"      </em>",
"      as a stimulator of inflammation in ocular rosacea is uncertain. A role in anterior blepharitis has been proposed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/60/34761/abstract/26,27\">",
"       26,27",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/46/36584?source=see_link&amp;anchor=H433276#H433276\">",
"       \"Rosacea: Pathogenesis, clinical features, and diagnosis\", section on 'Demodex'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further study is necessary to elucidate the pathogenic mechanisms of ocular rosacea. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/46/36584?source=see_link&amp;anchor=H394012131#H394012131\">",
"     \"Rosacea: Pathogenesis, clinical features, and diagnosis\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27345143\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ocular rosacea usually presents with abnormalities of the eyelids, conjunctiva, or cornea; rarely, the iris and sclera are affected. Although bilateral involvement typically occurs, the severity of clinical findings (particularly rosacea keratitis) may be asymmetrical [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34761/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4343694\">",
"    <span class=\"h2\">",
"     Eyelid and conjunctiva",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common findings in patients with ocular rosacea are blepharitis, lid margin telangiectasias, and conjunctival hyperemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34761/abstract/9\">",
"     9",
"    </a>",
"    ]. In addition, chalazion occurs more frequently among individuals with rosacea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34761/abstract/8,9,28,29\">",
"     8,9,28,29",
"    </a>",
"    ]. Symptoms of burning, itching, foreign body sensation, dryness, tearing, or photophobia, are also common. Often, the severity of these symptoms is greater than would be expected based upon the objective clinical findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34761/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1578650\">",
"    <span class=\"h3\">",
"     Blepharitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inflammation of the lid margins (marginal blepharitis) is a common finding in ocular rosacea that can also occur in a variety of other clinical settings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34761/abstract/30\">",
"     30",
"    </a>",
"    ]. Clinically, blepharitis may be anterior or posterior. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/38/19048?source=see_link\">",
"     \"Blepharitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Anterior blepharitis",
"      </strong>",
"      &ndash; Anterior blepharitis, an inflammatory process that involves the anterior lid margin and lash line, is characterized by lid margin edema and hyperemia, and accumulated squamous debris around the lash bases (",
"      <a class=\"graphic graphic_picture graphicRef64540 \" href=\"mobipreview.htm?28/6/28771\">",
"       picture 1",
"      </a>",
"      ). In a retrospective study of 88 patients evaluated for rosacea in an ophthalmology clinic, 44 percent were found to have anterior blepharitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/60/34761/abstract/9\">",
"       9",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Patients with anterior blepharitis frequently rub their eyelids in response to the commonly associated symptoms of itching and irritation. Chronic involvement eventually results in lid margin thickening and irregularity, vessel dilatation, and loss of the eyelashes (madarosis). The red and swollen appearance of the lid margins can be cosmetically distressing to these patients.",
"     </li>",
"     <li>",
"      <strong>",
"       Meibomian gland dysfunction (MGD, a form of posterior blepharitis)",
"      </strong>",
"      &ndash; The meibomian glands are situated within the substance of the lids and secrete an oily lipid which is the source of the superficial lipid layer of the tear film. This layer plays a key role in retarding evaporation of tear fluid from the eye and prevents ocular desiccation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/60/34761/abstract/31,32\">",
"       31,32",
"      </a>",
"      ]. Meibomian gland dysfunction is characterized by obstruction of the terminal ducts of the glands (",
"      <a class=\"graphic graphic_picture graphicRef78680 graphicRef58040 graphicRef66750 graphicRef81954 graphicRef59488 \" href=\"mobipreview.htm?3/0/3082\">",
"       picture 2A-E",
"      </a>",
"      ), loss of glandular tissue, and defective delivery of meibomian lipids to the tear film.",
"      <br/>",
"      <br/>",
"      Meibomian gland dysfunction is one of the most common features of ocular rosacea. In the retrospective study of 88 ophthalmology patients with rosacea referenced above, meibomian gland dysfunction was present in 85 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/60/34761/abstract/9\">",
"       9",
"      </a>",
"      ]. Frequently associated symptoms include dry eyes and ocular discomfort. Ophthalmologic examination reveals plugging of the meibomian orifices and a cloudy or opaque quality of expressed meibomian secretions (",
"      <a class=\"graphic graphic_picture graphicRef58040 \" href=\"mobipreview.htm?5/19/5438\">",
"       picture 2B",
"      </a>",
"      ); the ability to express the contents of the meibomian glands may be reduced. There is also increased vascularity (including telangiectasias) of the lid margin.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H73542767\">",
"    <span class=\"h3\">",
"     Conjunctival hyperemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conjunctival hyperemia (red appearance to the eyes due to dilated conjunctival vessels) is a common feature of ocular rosacea (",
"    <a class=\"graphic graphic_picture graphicRef54397 graphicRef72305 \" href=\"mobipreview.htm?18/63/19449\">",
"     picture 3A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34761/abstract/8,9,13,28\">",
"     8,9,13,28",
"    </a>",
"    ]. In retrospective studies of patients with rosacea who were evaluated in ophthalmology practices, lid margin telangiectasias and conjunctival hyperemia were each detected in 50 to 80 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34761/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1579318\">",
"    <span class=\"h3\">",
"     Chalazion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with rosacea are more susceptible to chalazion, an inflammatory, granulomatous lesion that forms around obstructed meibomian glands (",
"    <a class=\"graphic graphic_picture graphicRef80892 graphicRef62030 \" href=\"mobipreview.htm?19/34/20009\">",
"     picture 4A-B",
"    </a>",
"    ). In a series of 51 adult patients scheduled for the excision of chalazia, 55 percent had rosacea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34761/abstract/29\">",
"     29",
"    </a>",
"    ]. Moreover, chalazia may occur in 10 to 20 percent of ophthalmology patients with rosacea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34761/abstract/8,9,28\">",
"     8,9,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chalazia appear as firm, pea-sized swellings within the substance of the eyelid. Most patients develop a single chalazion at a time, although multiple lesions may also occur. Signs of inflammation on the overlying skin are often minimal, but may be present on the mucosal surface of the eyelid. Because pain is usually absent, the cosmetic appearance of the lesion or visual impairment due to its mass effect are often the greatest concerns for patients. Occasionally, an acute suppurative infection of the meibomian glands may occur (hordeolum internum). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/63/4088?source=see_link&amp;anchor=H5#H5\">",
"     \"Eyelid lesions\", section on 'Chalazion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H533258\">",
"    <span class=\"h3\">",
"     Stye (hordeolum externum)",
"    </span>",
"    &nbsp;&mdash;&nbsp;A stye is an acute and painful suppurative condition of an eyelash follicle corresponding to a furuncle of the skin (",
"    <a class=\"graphic graphic_picture graphicRef58059 \" href=\"mobipreview.htm?19/15/19699\">",
"     picture 5",
"    </a>",
"    ). It is usually caused by",
"    <em>",
"     Staphylococcus aureus",
"    </em>",
"    . It responds to treatment with hot compresses and local, or frequently systemic, antibiotic therapy. Occasionally, styes occur in patients with rosacea. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/63/4088?source=see_link&amp;anchor=H7#H7\">",
"     \"Eyelid lesions\", section on 'Hordeolum'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H533287\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other conjunctival findings reported in patients with rosacea include papillary and follicular reactions in the tarsal plate and conjunctival scarring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34761/abstract/9\">",
"     9",
"    </a>",
"    ]. This scarring may displace the meibomian gland orifices posteriorly into the tarsal mucosa, giving rise to a cicatricial form of meibomian gland dysfunction (",
"    <a class=\"graphic graphic_picture graphicRef59488 \" href=\"mobipreview.htm?4/12/4288\">",
"     picture 2E",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1579154\">",
"    <span class=\"h2\">",
"     Cornea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rosacea keratitis",
"    <strong>",
"    </strong>",
"    is the most serious ocular complication of rosacea and although its prevalence is low compared to that of blepharitis, it may cause blindness. It is a bilateral, relapsing keratitis, varying in severity between the two eyes. It begins in the nasal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    temporal periphery, or inferiorly, and may spread to involve the lower half to two-thirds of each cornea. At this stage it affects vision considerably.",
"   </p>",
"   <p>",
"    The initial attack, arising at or below the horizontal meridian, consists of a small, ulcerated, superficial peripheral",
"    <strong>",
"     stromal infiltrate",
"    </strong>",
"    (",
"    <a class=\"graphic graphic_picture graphicRef72305 \" href=\"mobipreview.htm?4/7/4214\">",
"     picture 3B",
"    </a>",
"    ). Subsequent infiltrates often occur in relation to a healed vascular lesion. Although episodes of disease activity may respond well to topical corticosteroid therapy, each new attack leads to further",
"    <strong>",
"     corneal thinning",
"    </strong>",
"    , opacity, and vessel invasion (",
"    <a class=\"graphic graphic_picture graphicRef61078 graphicRef74260 \" href=\"mobipreview.htm?8/1/8214\">",
"     picture 6A-B",
"    </a>",
"    ). With advanced disease, stromal loss may lead to the formation of a descemetocele (a thinning of the cornea down to the most posterior layer of the stroma) and a small risk for corneal perforation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34761/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is this clinical picture of centripetally advancing, nasal and temporal wings of corneal thinning, vascularization and opacity that most authors consider to be pathognomonic of ocular rosacea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34761/abstract/33\">",
"     33",
"    </a>",
"    ]. This viewpoint has been contested [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34761/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <strong>",
"     Superficial punctate keratitis",
"    </strong>",
"    (punctate epithelial erosions on the cornea) affecting the inferior portion of the cornea is a more common, but non-specific abnormality that may occur in up to 40 percent of patients with ocular rosacea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34761/abstract/8,9,28\">",
"     8,9,28",
"    </a>",
"    ]. Other potential corneal findings include pannus (a peripheral subepithelial vascularization) (",
"    <a class=\"graphic graphic_picture graphicRef72305 \" href=\"mobipreview.htm?4/7/4214\">",
"     picture 3B",
"    </a>",
"    ), and phlyctenule (a vascular corneal nodule) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34761/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4344077\">",
"    <span class=\"h2\">",
"     Dry eye",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dry eye can occur as a feature of ocular rosacea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34761/abstract/8,34-36\">",
"     8,34-36",
"    </a>",
"    ]. Symptoms of ocular discomfort and the pattern of ocular surface damage on ophthalmic examination (eg, corneal and conjunctival staining with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    ) are highly suggestive of dry eye.",
"   </p>",
"   <p>",
"    Evaporative dry eye results from extensive obstruction of the meibomian glands together with qualitative changes in their secretion. This leads to a deficiency of the tear film lipid layer, tear film instability, increased evaporation, and damage-causing tear hyperosmolarity. An aqueous tear-deficient form of dry eye due to a lacrimal insufficiency is also reported, although the reason for its association with ocular rosacea is obscure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34761/abstract/34,36\">",
"     34,36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H533345\">",
"    <span class=\"h2\">",
"     Other ocular tissues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional ocular findings that are infrequently associated with rosacea include iritis, episcleritis, and scleritis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4343774\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A diagnosis of ocular rosacea may be suspected when a patient with cutaneous rosacea exhibits ocular symptoms or signs. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Foreign body sensation, pain, itching, or burning sensations",
"     </li>",
"     <li>",
"      Signs of blepharitis, including lid margin swelling, redness, telangiectasia, or scale and debris in the lash line",
"     </li>",
"     <li>",
"      Conjunctival hyperemia",
"     </li>",
"     <li>",
"      Cloudy meibomian gland secretions consistent with meibomian gland dysfunction",
"     </li>",
"     <li>",
"      Corneal opacity",
"     </li>",
"     <li>",
"      A history of recurrent chalazion",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Since patients may not be aware of a connection between cutaneous rosacea and ocular symptoms, they may fail to mention such symptoms during an evaluation for cutaneous rosacea. Thus, all patients with cutaneous rosacea should be asked about the presence of ocular discomfort or visual changes. Early diagnosis of ocular rosacea is desirable, as treatment may reduce the risk for vision-threatening complications. Patients with features suggestive of ocular rosacea should be referred for ophthalmologic evaluation. (See",
"    <a class=\"local\" href=\"#H1164517\">",
"     'Indications for referral and follow-up'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The diagnosis of ocular rosacea in patients without concomitant cutaneous symptoms is difficult since clinical findings are generally nonspecific. However, since ocular rosacea may occur prior to the development of skin disease, this possibility should be considered in patients with any form of blepharitis, particularly in combination with a bilateral vascular keratitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4343814\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other etiologies that should be considered in patients with chronic blepharitis include seborrheic dermatitis, atopic dermatitis, contact dermatitis, and ocular cicatricial pemphigoid. Sebaceous carcinoma is a rare, but important additional consideration, particularly when conjunctival inflammation is unilateral or a nodule is present in the lid. In addition, in patients with corneal lesions, clinicians should remain cognizant of the possibility of bacterial or viral infection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/28/21961?source=see_link\">",
"     \"Seborrheic dermatitis in adolescents and adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/2/4138?source=see_link\">",
"     \"Ocular cicatricial pemphigoid\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/17/20760?source=see_link\">",
"     \"Conjunctivitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/63/4088?source=see_link&amp;anchor=H16#H16\">",
"     \"Eyelid lesions\", section on 'Sebaceous carcinoma'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/12/17607?source=see_link&amp;anchor=H10#H10\">",
"     \"Evaluation of the red eye\", section on 'Infectious keratitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4343782\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;While treatment options for ocular rosacea are established, high quality evidence to support the approach to treatment is often lacking.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1298958\">",
"    <span class=\"h2\">",
"     Local therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple clinical manifestations of ocular rosacea can be improved with local therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48257649\">",
"    <span class=\"h3\">",
"     Symptom management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ocular lubricants and topical nonsteroidal antiinflammatory agents can be beneficial for the management of symptoms in patients with ocular rosacea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34761/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1298973\">",
"    <span class=\"h3\">",
"     Blepharitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blepharitis is the most common manifestation of ocular rosacea and mild blepharitis often can be managed with lid hygiene, topical antibacterial agents, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/41/24211?source=see_link\">",
"     artificial tears",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H1298475\">",
"     'Topical antimicrobials'",
"    </a>",
"    below.) Of note, a committee-based review of the evidence on the management of meibomian gland dysfunction has been published [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34761/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1298951\">",
"    <span class=\"h4\">",
"     Lid hygiene and lid massage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lid hygiene is an important component of the treatment of blepharitis. In patients with rosacea and anterior blepharitis presenting with erythema and scaling in the lash line of the lid, either dilute baby shampoo (eg, one drop of shampoo in one tablespoon of water) applied with a cotton bud, commercial preparations, or a dilute bicarbonate solution [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34761/abstract/38\">",
"     38",
"    </a>",
"    ] can be used to cleanse the eyelid margins. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/38/19048?source=see_link&amp;anchor=H24#H24\">",
"     \"Blepharitis\", section on 'Lid washing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with meibomian gland dysfunction, the application of heat to closed lids for five to ten minutes per day (via warm compresses or commercial devices) increases fluidity of the meibomian gland secretions and allows lid massage to unblock meibomian ducts, thereby facilitating lipid delivery to the tear film [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34761/abstract/39\">",
"     39",
"    </a>",
"    ]. In turn, this improves spreading of the tear film during blinking and restores the evaporative barrier of the lipid layer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34761/abstract/40-45\">",
"     40-45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients should be instructed to perform lid massage immediately after the application of heat. One method is to apply a series of firm, stroking movements to the surface of the lids. Stroking can be performed with a firm object such as the flat surface of a rounded pencil, and pressure is applied from the periphery towards the lid margin, moving from the temporal to the nasal side. This is performed first on the upper lid with the eyes closed and then on the lower lid with the eyes open and in upward gaze. Lid massage is performed two times per day, and as improvement occurs, can be reduced to once daily. It is important to demonstrate the technique to the patient to ensure safety. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/38/19048?source=see_link&amp;anchor=H22#H22\">",
"     \"Blepharitis\", section on 'Warm compresses'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/38/19048?source=see_link&amp;anchor=H23#H23\">",
"     \"Blepharitis\", section on 'Lid massage'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1298475\">",
"    <span class=\"h4\">",
"     Topical antimicrobials",
"    </span>",
"    &nbsp;&mdash;&nbsp;The application of topical antimicrobial agents to the lid margins may improve blepharitis through reduction of the bacterial load at the lid margins, antiinflammatory properties, or other mechanisms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34761/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H73542216\">",
"     'Pathogenesis'",
"    </a>",
"    above.) A variety of broad-spectrum ophthalmic topical antimicrobials, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/20/6469?source=see_link\">",
"     bacitracin",
"    </a>",
"    ,",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?17/20/17733?source=see_link\">",
"      polymyxin B",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?25/36/26182?source=see_link\">",
"      trimethoprim",
"     </a>",
"     ,",
"    </span>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/9/21651?source=see_link\">",
"     fusidic acid",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34761/abstract/47\">",
"     47",
"    </a>",
"    ], and other agents have been utilized for anterior blepharitis and meibomian gland dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34761/abstract/12\">",
"     12",
"    </a>",
"    ]. In several open label studies of patients with blepharitis, improvement in clinical findings and meibomian gland function have occurred during treatment with topical azithromycin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34761/abstract/48-52\">",
"     48-52",
"    </a>",
"    ]. Fusidic acid is not available in the United States. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/38/19048?source=see_link&amp;anchor=H26#H26\">",
"     \"Blepharitis\", section on 'Topical antibiotics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     Metronidazole",
"    </a>",
"    gel, an effective therapy for cutaneous rosacea, has been advocated by some clinicians as a treatment for ocular rosacea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34761/abstract/12,53\">",
"     12,53",
"    </a>",
"    ]. In an observer-blinded study in 10 patients with ocular rosacea in whom one eye was treated with metronidazole 1% gel plus lid hygiene and the other eye was treated with lid hygiene alone, 8 out of 10 metronidazole-treated eyes improved compared with 5 out of 10 eyes in the other group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34761/abstract/54\">",
"     54",
"    </a>",
"    ]. An ophthalmic preparation of metronidazole is not commercially available, and the safety of the non-ophthalmic preparations is not definitively established. However, based upon the limited available data, the drug seems to be well-tolerated when used for this indication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34761/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1298530\">",
"    <span class=\"h4\">",
"     Topical corticosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of topical corticosteroids in patients with rosacea-associated blepharitis is usually reserved for patients with marked eyelid inflammation. Treatment should limited to two to three weeks to reduce the risk for corticosteroid-induced cataract formation and glaucoma. Low potency agents such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/13/20691?source=see_link\">",
"     rimexolone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/48/39684?source=see_link\">",
"     loteprednol",
"    </a>",
"    etabonate, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/49/41748?source=see_link\">",
"     fluorometholone",
"    </a>",
"    , are preferred to reduce the risk for adverse effects. Topical corticosteroids should only be prescribed in conjunction with an ophthalmologist. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/38/19048?source=see_link&amp;anchor=H28#H28\">",
"     \"Blepharitis\", section on 'Topical glucocorticoids'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1298965\">",
"    <span class=\"h2\">",
"     Systemic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients who fail to improve adequately with local therapy alone, systemic antibiotic therapy can be beneficial for the improvement of rosaceal meibomian gland dysfunction and the effects of this dysfunction on ocular tissues. Since similar agents are utilized for the treatment of moderate to severe cutaneous papulopustular rosacea, patients with milder ocular disease and significant cutaneous symptoms may also receive oral antibiotic therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/24/29066?source=see_link&amp;anchor=H2325908#H2325908\">",
"     \"Management of rosacea\", section on 'Moderate to severe disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1298670\">",
"    <span class=\"h3\">",
"     Oral antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral tetracyclines are the most commonly used systemic agents for ocular rosacea, and have been linked with improvement in multiple manifestations, including abnormalities of the eyelids, conjunctiva, and cornea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34761/abstract/15,28,55\">",
"     15,28,55",
"    </a>",
"    ]. Oral macrolides may be utilized in young children and other patients who are unable to tolerate tetracyclines.",
"   </p>",
"   <p>",
"    The reasons for the efficacy of these systemic antibiotics are not definitively known; potential mechanisms of action include their antimicrobial and antiinflammatory effects. Other factors, such as beneficial effects on meibomian gland secretion, also may play important roles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34761/abstract/12,21\">",
"     12,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1195882\">",
"    <span class=\"h4\">",
"     Tetracyclines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two placebo-controlled randomized trials have evaluated the efficacy of oral tetracyclines in ocular rosacea. The trials focused on the use of oxytetracycline, a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    derivative that is available in Europe, but not in the United States. In a randomized trial of 35 patients with ocular rosacea who were treated with oxytetracycline 250 mg twice daily or a placebo pill, treatment with the drug for six weeks was associated with a significantly greater likelihood for disease remission (65 versus 28 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34761/abstract/55\">",
"     55",
"    </a>",
"    ]. The other randomized trial was a cross-over trial in which the administration of tetracycline (250 mg twice daily for two months following a two-month placebo phase) in a subset of 10 patients with rosacea-associated blepharitis was associated with clinical improvement in 50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34761/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of other tetracyclines, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    for ocular rosacea, is supported by uncontrolled studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34761/abstract/56\">",
"     56",
"    </a>",
"    ]. In a retrospective study in which 113 patients with ocular rosacea were treated with tetracycline 250 mg four times per day or doxycycline 100 mg per day, all except two patients responded well to therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34761/abstract/8\">",
"     8",
"    </a>",
"    ]. Additionally, in a prospective study of 39 patients with ocular rosacea, treatment with doxycycline 100 mg per day for 12 weeks was associated with improvements in ocular disease and tear film stability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34761/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Typical adult doses for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    -class antibiotics in ocular rosacea are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"       Tetracycline",
"      </a>",
"      <strong>",
"      </strong>",
"      &ndash; 500 to 1000 mg per day",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"       Doxycycline",
"      </a>",
"      <strong>",
"      </strong>",
"      &ndash; 100 to 200 mg per day",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/10/3240?source=see_link\">",
"       Minocycline",
"      </a>",
"      <strong>",
"      </strong>",
"      &ndash; 100 to 200 mg per day",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Subantimicrobial doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    are often used for the treatment of cutaneous papulopustular rosacea, and a retrospective study in which seven patients with ocular rosacea improved during treatment with 40 mg per day of a slow release formulation of doxycycline suggests that low dose doxycycline may also be of benefit for ocular disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34761/abstract/57\">",
"     57",
"    </a>",
"    ]. Advantages of subantimicrobial dosing include reduced risks for drug-related adverse effects and the induction of antibiotic resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34761/abstract/58\">",
"     58",
"    </a>",
"    ]. However, the onset of action may be delayed; on average, slightly more than two months of treatment were required to achieve initial clinical signs of improvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34761/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tetracyclines cannot be utilized in children under the age of nine due to a risk for permanent tooth discoloration. Macrolide antibiotics, which also have antiinflammatory effects, are an additional systemic treatment option for young children and other patients who are unable to tolerate tetracyclines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1195889\">",
"    <span class=\"h4\">",
"     Macrolides",
"    </span>",
"    &nbsp;&mdash;&nbsp;No randomized trials have evaluated the efficacy of oral macrolides for ocular rosacea, but improvement in children during treatment with oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    has been reported in retrospective studies and a small case series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34761/abstract/3,5,6\">",
"     3,5,6",
"    </a>",
"    ]. In addition, oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    (500 mg on three consecutive days per week for four weeks) was associated with improvements in ocular disease in an open label study in adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34761/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment regimens have varied widely. Children have responded to 20 to 50",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    given in two to three divided doses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34761/abstract/6,60\">",
"     6,60",
"    </a>",
"    ]; adults have been treated with 200 to 400 mg administered two to three times per day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34761/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/24/29066?source=see_link&amp;anchor=H2326144#H2326144\">",
"     \"Management of rosacea\", section on 'Alternative oral antibiotics'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1195964\">",
"    <span class=\"h4\">",
"     Metronidazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    , an antibacterial agent used in the treatment of cutaneous rosacea, has been used by some clinicians for the treatment of ocular rosacea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34761/abstract/53,61\">",
"     53,61",
"    </a>",
"    ]. In a small retrospective study, children with ocular rosacea responded to metronidazole 20 to 30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day given for at least two months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34761/abstract/61\">",
"     61",
"    </a>",
"    ]. Of note, alcohol must be avoided during treatment with metronidazole due to the risk for a disulfiram-like reaction, making treatment with this agent a less desirable option for some patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1195971\">",
"    <span class=\"h4\">",
"     Treatment course",
"    </span>",
"    &nbsp;&mdash;&nbsp;Improvement with oral antibiotic therapy is usually noted within a few weeks after initiating therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34761/abstract/28,55\">",
"     28,55",
"    </a>",
"    ]. However, the optimal duration of therapy is unknown, and relapse of disease after the discontinuation of treatment is common [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34761/abstract/28\">",
"     28",
"    </a>",
"    ]. Typically, oral antibiotic therapy with tetracyclines or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    is continued until adequate improvement is achieved (usually 6 to 12 weeks), and subsequently the dose is tapered and oral treatment discontinued over the course of one to two months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34761/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. This course of antibiotic therapy can be repeated for future disease flares.",
"   </p>",
"   <p>",
"    Patients who require reinitiation of systemic therapy more than two or three times per year despite the use of appropriate topical interventions (eg, routine lid hygiene) may require continuous antibiotic therapy to suppress the disease for several years or more [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34761/abstract/14\">",
"     14",
"    </a>",
"    ]. Patients should be treated with the lowest dose that effectively controls clinical signs and symptoms. Periodically, therapy can be withdrawn to assess for the need for continuous therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1164565\">",
"    <span class=\"h3\">",
"     Omega-3 fatty acids",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of omega-3 fatty acid supplementation in ocular rosacea is uncertain. Increased consumption of omega-3 fatty acids may be beneficial for the treatment of dry eyes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34761/abstract/64-66\">",
"     64-66",
"    </a>",
"    ]. However, there is not yet sufficient evidence to support for the utilization of omega-3 fatty acid supplementation for meibomian gland dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34761/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/11/25784?source=see_link&amp;anchor=H20#H20\">",
"     \"Dry eyes\", section on 'Other'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1165104\">",
"    <span class=\"h3\">",
"     Oral retinoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    is occasionally used for the treatment of severe cutaneous rosacea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34761/abstract/69-71\">",
"     69-71",
"    </a>",
"    ], the impact of retinoids on ocular rosacea has not been explored. Meibomian gland dysfunction has been reported in patients treated with isotretinoin for acne vulgaris [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34761/abstract/72\">",
"     72",
"    </a>",
"    ], and this finding suggests that its use is contraindicated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34761/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1195191\">",
"    <span class=\"h2\">",
"     Dry eyes",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/41/24211?source=see_link\">",
"     Artificial tears",
"    </a>",
"    , ocular lubricants, topical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , dietary alterations, punctal occlusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34761/abstract/12,74\">",
"     12,74",
"    </a>",
"    ], and protective eyewear are treatment options for dry eyes. In one randomized trial in which patients with ocular rosacea were treated with cyclosporine ophthalmic emulsion 0.05% or an artificial tear solution, statistically significant improvements in Schirmer scores and tear break-up time scores were seen in the group who received cyclosporine, but not in the artificial tear group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34761/abstract/75\">",
"     75",
"    </a>",
"    ]. The treatment options for dry eyes are discussed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/11/25784?source=see_link&amp;anchor=H16#H16\">",
"     \"Dry eyes\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1195198\">",
"    <span class=\"h2\">",
"     Keratitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Superficial punctate keratitis secondary to blepharitis or dry eye improves with treatment of these disorders. Rosacea keratitis should be suspected in patients with ocular pain, corneal opacity, and visual impairment, and is best managed in conjunction with an ophthalmologist. Topical corticosteroid therapy is typically used for management. In addition, beneficial effects of oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34761/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1579154\">",
"     'Cornea'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Patients who develop permanent damage to the cornea and associated visual impairment may require penetrating or lamellar keratoplasty to repair corneal perforation or opacification [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34761/abstract/12\">",
"     12",
"    </a>",
"    ]. Of note, the chronic, inflammatory nature of rosacea may increase the risk for neovascularization and opacification of the graft [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34761/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1195294\">",
"    <span class=\"h2\">",
"     Chalazion/hordeolum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Warm compresses are the first-line treatment for chalazion and hordeolum. Antibiotic therapy for hordeola or surgical intervention may be necessary if lesions fail to improve. The management of chalazia and hordeola is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/63/4088?source=see_link&amp;anchor=H5#H5\">",
"     \"Eyelid lesions\", section on 'Chalazion'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/63/4088?source=see_link&amp;anchor=H7#H7\">",
"     \"Eyelid lesions\", section on 'Hordeolum'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1164517\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR REFERRAL AND FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with cutaneous rosacea should be assessed for symptoms and signs of ocular rosacea. Symptoms of ocular discomfort and signs of lid margin inflammation, conjunctival hyperemia, or corneal opacity are all indications for ophthalmologic referral. Early diagnosis and treatment of lid and corneal disease are essential to prevent further complications. Patients with ocular pain or visual changes should be immediately referred for ophthalmologic evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1164524\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ocular rosacea is a chronic disorder that tends to persist if untreated. Rarely, the disease can result in severe corneal damage and vision loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34761/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/56/18305?source=see_link\">",
"       \"Patient information: Chalazion (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1164531\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ocular rosacea is a subtype of rosacea that is characterized by inflammatory, vascular, and glandular changes involving the eyelids and ocular tissues. Middle-aged adults are most frequently affected. Occasionally, ocular rosacea occurs in children. (See",
"      <a class=\"local\" href=\"#H8274783\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with ocular rosacea may present with a wide variety of symptoms, including ocular irritation, itching, burning, pain, tearing, dry eyes, or photophobia. Physical examination often demonstrates nonspecific abnormalities of the eyelids, conjunctiva, or cornea. (See",
"      <a class=\"local\" href=\"#H27345143\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Anterior blepharitis is a frequent manifestation of rosacea that presents with edema, hyperemia, and scale involving the lid margins (",
"      <a class=\"graphic graphic_picture graphicRef54397 \" href=\"mobipreview.htm?17/27/17843\">",
"       picture 3A",
"      </a>",
"      ). Ocular itching and discomfort are common associated symptoms. (See",
"      <a class=\"local\" href=\"#H1578650\">",
"       'Blepharitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Meibomian gland dysfunction, a form of posterior blepharitis, occurs in ocular rosacea as a result of meibomian gland obstruction (",
"      <a class=\"graphic graphic_picture graphicRef78680 graphicRef58040 graphicRef66750 graphicRef81954 graphicRef59488 \" href=\"mobipreview.htm?3/0/3082\">",
"       picture 2A-E",
"      </a>",
"      ). Patients with meibomian gland dysfunction may complain of dry eyes due to the resultant abnormalities in the lipid component of the tear film. Chalazion, a granulomatous, pea-like nodule that develops in the eyelid, may also develop as a consequence of meibomian gland obstruction (",
"      <a class=\"graphic graphic_picture graphicRef80892 graphicRef62030 \" href=\"mobipreview.htm?19/34/20009\">",
"       picture 4A-B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1578650\">",
"       'Blepharitis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1579318\">",
"       'Chalazion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Superficial punctate keratitis is one of the most common corneal abnormalities associated with ocular rosacea. &nbsp;More rarely, a recurrent bilateral vascular keratitis can lead to corneal thinning, scarring, and visual loss (",
"      <a class=\"graphic graphic_picture graphicRef78680 graphicRef58040 graphicRef66750 \" href=\"mobipreview.htm?10/28/10694\">",
"       picture 2A-C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1579154\">",
"       'Cornea'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of ocular rosacea is usually made based upon the identification of consistent ocular symptoms in patients with cutaneous manifestations of rosacea. Occasionally, ocular rosacea develops in the absence of cutaneous symptoms. Recognition of the diagnosis is difficult in such patients. (See",
"      <a class=\"local\" href=\"#H4343774\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Local therapies such as lid hygiene, ocular lubricants, topical antimicrobials, and topical nonsteroidal antiinflammatory agents can be useful for the management of mild manifestations of ocular rosacea. Topical corticosteroid use should only be prescribed in conjunction with an ophthalmologist and should be limited to short treatment courses in patients who require rapid improvement of severe inflammation. (See",
"      <a class=\"local\" href=\"#H1298958\">",
"       'Local therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Oral antibiotic therapy can effectively treat multiple manifestations of ocular rosacea. For patients with moderate to severe ocular rosacea or who fail to respond to local therapies, we suggest treatment with oral tetracyclines (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). The course of treatment is usually a few months; long term oral antibiotic treatment may be necessary in patients who have frequent relapses after the discontinuation of systemic therapy. (See",
"      <a class=\"local\" href=\"#H1298670\">",
"       'Oral antibiotics'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34761/abstract/1\">",
"      Wilkin J, Dahl M, Detmar M, et al. Standard classification of rosacea: Report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol 2002; 46:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34761/abstract/2\">",
"      Wilkin J, Dahl M, Detmar M, et al. Standard grading system for rosacea: report of the National Rosacea Society Expert Committee on the classification and staging of rosacea. J Am Acad Dermatol 2004; 50:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34761/abstract/3\">",
"      Drolet B, Paller AS. Childhood rosacea. Pediatr Dermatol 1992; 9:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34761/abstract/4\">",
"      Erzurum SA, Feder RS, Greenwald MJ. Acne rosacea with keratitis in childhood. Arch Ophthalmol 1993; 111:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34761/abstract/5\">",
"      Donaldson KE, Karp CL, Dunbar MT. Evaluation and treatment of children with ocular rosacea. Cornea 2007; 26:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34761/abstract/6\">",
"      Nazir SA, Murphy S, Siatkowski RM, et al. Ocular rosacea in childhood. Am J Ophthalmol 2004; 137:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34761/abstract/7\">",
"      BORRIE P. Rosacea with special reference to its ocular manifestations. Br J Dermatol 1953; 65:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34761/abstract/8\">",
"      Akpek EK, Merchant A, Pinar V, Foster CS. Ocular rosacea: patient characteristics and follow-up. Ophthalmology 1997; 104:1863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34761/abstract/9\">",
"      Ghanem VC, Mehra N, Wong S, Mannis MJ. The prevalence of ocular signs in acne rosacea: comparing patients from ophthalmology and dermatology clinics. Cornea 2003; 22:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34761/abstract/10\">",
"      Browning DJ, Proia AD. Ocular rosacea. Surv Ophthalmol 1986; 31:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34761/abstract/11\">",
"      Starr PA, Macdonald A. Oculocutaneous aspects of rosacea. Proc R Soc Med 1969; 62:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34761/abstract/12\">",
"      Oltz M, Check J. Rosacea and its ocular manifestations. Optometry 2011; 82:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34761/abstract/13\">",
"      Eiseman AS. The ocular manifestations of atopic dermatitis and rosacea. Curr Allergy Asthma Rep 2006; 6:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34761/abstract/14\">",
"      Michel JL, Cabibel F. [Frequency, severity and treatment of ocular rosacea during cutaneous rosacea]. Ann Dermatol Venereol 2003; 130:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34761/abstract/15\">",
"      Quarterman MJ, Johnson DW, Abele DC, et al. Ocular rosacea. Signs, symptoms, and tear studies before and after treatment with doxycycline. Arch Dermatol 1997; 133:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34761/abstract/16\">",
"      Barton K, Monroy DC, Nava A, Pflugfelder SC. Inflammatory cytokines in the tears of patients with ocular rosacea. Ophthalmology 1997; 104:1868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34761/abstract/17\">",
"      Barton K, Nava A, Monroy DC, Pflugfelder SC. Cytokines and tear function in ocular surface disease. Adv Exp Med Biol 1998; 438:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34761/abstract/18\">",
"      Afonso AA, Sobrin L, Monroy DC, et al. Tear fluid gelatinase B activity correlates with IL-1alpha concentration and fluorescein clearance in ocular rosacea. Invest Ophthalmol Vis Sci 1999; 40:2506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34761/abstract/19\">",
"      Sobrin L, Liu Z, Monroy DC, et al. Regulation of MMP-9 activity in human tear fluid and corneal epithelial culture supernatant. Invest Ophthalmol Vis Sci 2000; 41:1703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34761/abstract/20\">",
"      Dougherty JM, McCulley JP. Comparative bacteriology of chronic blepharitis. Br J Ophthalmol 1984; 68:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34761/abstract/21\">",
"      Stone DU, Chodosh J. Ocular rosacea: an update on pathogenesis and therapy. Curr Opin Ophthalmol 2004; 15:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34761/abstract/22\">",
"      Dougherty JM, McCulley JP, Silvany RE, Meyer DR. The role of tetracycline in chronic blepharitis. Inhibition of lipase production in staphylococci. Invest Ophthalmol Vis Sci 1991; 32:2970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34761/abstract/23\">",
"      Shine WE, McCulley JP, Pandya AG. Minocycline effect on meibomian gland lipids in meibomianitis patients. Exp Eye Res 2003; 76:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34761/abstract/24\">",
"      Ta CN, Shine WE, McCulley JP, et al. Effects of minocycline on the ocular flora of patients with acne rosacea or seborrheic blepharitis. Cornea 2003; 22:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34761/abstract/25\">",
"      Souchier M, Joffre C, Gr&eacute;goire S, et al. Changes in meibomian fatty acids and clinical signs in patients with meibomian gland dysfunction after minocycline treatment. Br J Ophthalmol 2008; 92:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34761/abstract/26\">",
"      Li J, O'Reilly N, Sheha H, et al. Correlation between ocular Demodex infestation and serum immunoreactivity to Bacillus proteins in patients with Facial rosacea. Ophthalmology 2010; 117:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34761/abstract/27\">",
"      Lacey N, Kavanagh K, Tseng SC. Under the lash: Demodex mites in human diseases. Biochem (Lond) 2009; 31:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34761/abstract/28\">",
"      Jenkins MS, Brown SI, Lempert SL, Weinberg RJ. Ocular rosacea. Am J Ophthalmol 1979; 88:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34761/abstract/29\">",
"      Lempert SL, Jenkins MS, Brown SI. Chalazia and rosacea. Arch Ophthalmol 1979; 97:1652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34761/abstract/30\">",
"      Lemp MA, Nichols KK. Blepharitis in the United States 2009: a survey-based perspective on prevalence and treatment. Ocul Surf 2009; 7:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34761/abstract/31\">",
"      Foulks GN, Bron AJ. Meibomian gland dysfunction: a clinical scheme for description, diagnosis, classification, and grading. Ocul Surf 2003; 1:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34761/abstract/32\">",
"      Bron AJ, Tiffany JM, Gouveia SM, et al. Functional aspects of the tear film lipid layer. Exp Eye Res 2004; 78:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34761/abstract/33\">",
"      GOLDSMITH AJ. The ocular manifestations of rosacea. Br J Dermatol 1953; 65:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34761/abstract/34\">",
"      Lemp MA, Mahmood MA, Weiler HH. Association of rosacea and keratoconjunctivitis sicca. Arch Ophthalmol 1984; 102:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34761/abstract/35\">",
"      Gudmundsen KJ, O'Donnell BF, Powell FC. Schirmer testing for dry eyes in patients with rosacea. J Am Acad Dermatol 1992; 26:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34761/abstract/36\">",
"      Ko&ccedil;ak-Altintas AG, Kocak-Midilliolu I, G&uuml;l U, et al. Impression cytology and ocular characteristics in ocular rosacea. Eur J Ophthalmol 2003; 13:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34761/abstract/37\">",
"      Geerling G, Tauber J, Baudouin C, et al. The international workshop on meibomian gland dysfunction: report of the subcommittee on management and treatment of meibomian gland dysfunction. Invest Ophthalmol Vis Sci 2011; 52:2050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34761/abstract/38\">",
"      Coroneo M. Management of chronic blepharitis. Arch Ophthalmol 1989; 107:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34761/abstract/39\">",
"      Blackie CA, Korb DR, Knop E, et al. Nonobvious obstructive meibomian gland dysfunction. Cornea 2010; 29:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34761/abstract/40\">",
"      Blackie CA, Solomon JD, Greiner JV, et al. Inner eyelid surface temperature as a function of warm compress methodology. Optom Vis Sci 2008; 85:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34761/abstract/41\">",
"      Matsumoto Y, Dogru M, Goto E, et al. Efficacy of a new warm moist air device on tear functions of patients with simple meibomian gland dysfunction. Cornea 2006; 25:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34761/abstract/42\">",
"      Olson MC, Korb DR, Greiner JV. Increase in tear film lipid layer thickness following treatment with warm compresses in patients with meibomian gland dysfunction. Eye Contact Lens 2003; 29:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34761/abstract/43\">",
"      Mitra M, Menon GJ, Casini A, et al. Tear film lipid layer thickness and ocular comfort after meibomian therapy via latent heat with a novel device in normal subjects. Eye (Lond) 2005; 19:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34761/abstract/44\">",
"      Goto E, Monden Y, Takano Y, et al. Treatment of non-inflamed obstructive meibomian gland dysfunction by an infrared warm compression device. Br J Ophthalmol 2002; 86:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34761/abstract/45\">",
"      Mori A, Shimazaki J, Shimmura S, et al. Disposable eyelid-warming device for the treatment of meibomian gland dysfunction. Jpn J Ophthalmol 2003; 47:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34761/abstract/46\">",
"      Sadrai Z, Hajrasouliha AR, Chauhan S, et al. Effect of topical azithromycin on corneal innate immune responses. Invest Ophthalmol Vis Sci 2011; 52:2525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34761/abstract/47\">",
"      Seal DV, Wright P, Ficker L, et al. Placebo controlled trial of fusidic acid gel and oxytetracycline for recurrent blepharitis and rosacea. Br J Ophthalmol 1995; 79:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34761/abstract/48\">",
"      Haque RM, Torkildsen GL, Brubaker K, et al. Multicenter open-label study evaluating the efficacy of azithromycin ophthalmic solution 1% on the signs and symptoms of subjects with blepharitis. Cornea 2010; 29:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34761/abstract/49\">",
"      Opitz DL, Tyler KF. Efficacy of azithromycin 1% ophthalmic solution for treatment of ocular surface disease from posterior blepharitis. Clin Exp Optom 2011; 94:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34761/abstract/50\">",
"      Luchs J. Efficacy of topical azithromycin ophthalmic solution 1% in the treatment of posterior blepharitis. Adv Ther 2008; 25:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34761/abstract/51\">",
"      Foulks GN, Borchman D, Yappert M, et al. Topical azithromycin therapy for meibomian gland dysfunction: clinical response and lipid alterations. Cornea 2010; 29:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34761/abstract/52\">",
"      John T, Shah AA. Use of azithromycin ophthalmic solution in the treatment of chronic mixed anterior blepharitis. Ann Ophthalmol (Skokie) 2008; 40:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34761/abstract/53\">",
"      Kligman AM. Ocular rosacea. Current concepts and therapy. Arch Dermatol 1997; 133:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34761/abstract/54\">",
"      Barnhorst DA Jr, Foster JA, Chern KC, Meisler DM. The efficacy of topical metronidazole in the treatment of ocular rosacea. Ophthalmology 1996; 103:1880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34761/abstract/55\">",
"      Bartholomew RS, Reid BJ, Cheesbrough MJ, et al. Oxytetracycline in the treatment of ocular rosacea: a double-blind trial. Br J Ophthalmol 1982; 66:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34761/abstract/56\">",
"      Stone DU, Chodosh J. Oral tetracyclines for ocular rosacea: an evidence-based review of the literature. Cornea 2004; 23:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34761/abstract/57\">",
"      Pfeffer I, Borelli C, Zierhut M, Schaller M. Treatment of ocular rosacea with 40 mg doxycycline in a slow release form. J Dtsch Dermatol Ges 2011; 9:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34761/abstract/58\">",
"      Del Rosso JQ, Schlessinger J, Werschler P. Comparison of anti-inflammatory dose doxycycline versus doxycycline 100 mg in the treatment of rosacea. J Drugs Dermatol 2008; 7:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34761/abstract/59\">",
"      Bakar O, Demircay Z, Toker E, Cakir S. Ocular signs, symptoms and tear function tests of papulopustular rosacea patients receiving azithromycin. J Eur Acad Dermatol Venereol 2009; 23:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34761/abstract/60\">",
"      Cetinkaya A, Akova YA. Pediatric ocular acne rosacea: long-term treatment with systemic antibiotics. Am J Ophthalmol 2006; 142:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34761/abstract/61\">",
"      Chamaillard M, Mortemousque B, Boralevi F, et al. Cutaneous and ocular signs of childhood rosacea. Arch Dermatol 2008; 144:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34761/abstract/62\">",
"      Powell FC. Clinical practice. Rosacea. N Engl J Med 2005; 352:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34761/abstract/63\">",
"      Tanzi EL, Weinberg JM. The ocular manifestations of rosacea. Cutis 2001; 68:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34761/abstract/64\">",
"      Miljanovi B, Trivedi KA, Dana MR, et al. Relation between dietary n-3 and n-6 fatty acids and clinically diagnosed dry eye syndrome in women. Am J Clin Nutr 2005; 82:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34761/abstract/65\">",
"      Wojtowicz JC, Butovich I, Uchiyama E, et al. Pilot, prospective, randomized, double-masked, placebo-controlled clinical trial of an omega-3 supplement for dry eye. Cornea 2011; 30:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34761/abstract/66\">",
"      Kokke KH, Morris JA, Lawrenson JG. Oral omega-6 essential fatty acid treatment in contact lens associated dry eye. Cont Lens Anterior Eye 2008; 31:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34761/abstract/67\">",
"      Pinna A, Piccinini P, Carta F. Effect of oral linoleic and gamma-linolenic acid on meibomian gland dysfunction. Cornea 2007; 26:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34761/abstract/68\">",
"      Macsai MS. The role of omega-3 dietary supplementation in blepharitis and meibomian gland dysfunction (an AOS thesis). Trans Am Ophthalmol Soc 2008; 106:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34761/abstract/69\">",
"      Gollnick H, Blume-Peytavi U, Szab&oacute; EL, et al. Systemic isotretinoin in the treatment of rosacea - doxycycline- and placebo-controlled, randomized clinical study. J Dtsch Dermatol Ges 2010; 8:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34761/abstract/70\">",
"      Erdogan FG, Yurtsever P, Aksoy D, Eskioglu F. Efficacy of low-dose isotretinoin in patients with treatment-resistant rosacea. Arch Dermatol 1998; 134:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34761/abstract/71\">",
"      Hoting E, Paul E, Plewig G. Treatment of rosacea with isotretinoin. Int J Dermatol 1986; 25:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34761/abstract/72\">",
"      Mathers WD, Shields WJ, Sachdev MS, et al. Meibomian gland morphology and tear osmolarity: changes with Accutane therapy. Cornea 1991; 10:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34761/abstract/73\">",
"      Gauwerky K, Kl&ouml;vekorn W, Korting HC, et al. Rosacea. J Dtsch Dermatol Ges 2009; 7:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34761/abstract/74\">",
"      Ervin AM, Wojciechowski R, Schein O. Punctal occlusion for dry eye syndrome. Cochrane Database Syst Rev 2010; :CD006775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34761/abstract/75\">",
"      Schechter BA, Katz RS, Friedman LS. Efficacy of topical cyclosporine for the treatment of ocular rosacea. Adv Ther 2009; 26:651.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13620 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.55.141.10-024AF9ABBA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_60_34761=[""].join("\n");
var outline_f33_60_34761=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1164531\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27345122\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8274783\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H73542216\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27345143\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4343694\">",
"      Eyelid and conjunctiva",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1578650\">",
"      - Blepharitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H73542767\">",
"      - Conjunctival hyperemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1579318\">",
"      - Chalazion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H533258\">",
"      - Stye (hordeolum externum)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H533287\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1579154\">",
"      Cornea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4344077\">",
"      Dry eye",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H533345\">",
"      Other ocular tissues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4343774\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4343814\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4343782\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1298958\">",
"      Local therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H48257649\">",
"      - Symptom management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1298973\">",
"      - Blepharitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1298951\">",
"      Lid hygiene and lid massage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1298475\">",
"      Topical antimicrobials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1298530\">",
"      Topical corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1298965\">",
"      Systemic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1298670\">",
"      - Oral antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1195882\">",
"      Tetracyclines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1195889\">",
"      Macrolides",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1195964\">",
"      Metronidazole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1195971\">",
"      Treatment course",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1164565\">",
"      - Omega-3 fatty acids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1165104\">",
"      - Oral retinoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1195191\">",
"      Dry eyes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1195198\">",
"      Keratitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1195294\">",
"      Chalazion/hordeolum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1164517\">",
"      INDICATIONS FOR REFERRAL AND FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1164524\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1164531\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/13620\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13620|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?28/6/28771\" title=\"picture 1\">",
"      Anterior blepharitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?26/0/26626\" title=\"picture 2A\">",
"      Meibomian gland dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?5/19/5438\" title=\"picture 2B\">",
"      Meibomian gland dysfunction 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?15/2/15406\" title=\"picture 2C\">",
"      Meibomian gland dysfunction 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?18/46/19169\" title=\"picture 2D\">",
"      Meibomian gland dysfunction 4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?4/12/4288\" title=\"picture 2E\">",
"      Meibomian gland dysfunction - cicatricial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?17/27/17843\" title=\"picture 3A\">",
"      Ocular rosacea telangiectasias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?4/7/4214\" title=\"picture 3B\">",
"      Rosacea keratitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?28/6/28774\" title=\"picture 4A\">",
"      Chalazion upper eyelid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?23/30/24034\" title=\"picture 4B\">",
"      Chalazion 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?19/15/19699\" title=\"picture 5\">",
"      Stye - lower lid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?30/39/31344\" title=\"picture 6A\">",
"      Rosacea keratitis - quiescent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?9/41/9873\" title=\"picture 6B\">",
"      Rosacea keratitis - neovascularization",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/38/19048?source=related_link\">",
"      Blepharitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/17/20760?source=related_link\">",
"      Conjunctivitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/11/25784?source=related_link\">",
"      Dry eyes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/12/17607?source=related_link\">",
"      Evaluation of the red eye",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/63/4088?source=related_link\">",
"      Eyelid lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/24/29066?source=related_link\">",
"      Management of rosacea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/2/4138?source=related_link\">",
"      Ocular cicatricial pemphigoid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/56/18305?source=related_link\">",
"      Patient information: Chalazion (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/46/36584?source=related_link\">",
"      Rosacea: Pathogenesis, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/28/21961?source=related_link\">",
"      Seborrheic dermatitis in adolescents and adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_60_34762="Treatment of idiopathic pulmonary fibrosis";
var content_f33_60_34762=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of idiopathic pulmonary fibrosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/60/34762/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/60/34762/contributors\">",
"     Talmadge E King, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/60/34762/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/60/34762/contributors\">",
"     Kevin R Flaherty, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/60/34762/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/60/34762/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/60/34762/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Idiopathic pulmonary fibrosis (IPF, also called cryptogenic fibrosing alveolitis) is specific form of chronic, progressive, fibrosing interstitial pneumonia of unknown cause, occurring in adults and limited to the lungs. It is associated with the histopathologic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiologic pattern of usual interstitial pneumonia (UIP). In the past, treatment was aimed at minimizing inflammation and slowing the progression from inflammation to fibrosis. However, the underlying lesion in IPF may be more fibrotic than inflammatory, explaining why few patients respond to antiinflammatory therapies and the prognosis remains poor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following questions will be discussed in this topic review, although considerable uncertainty remains about the answers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/2,4,5\">",
"     2,4,5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Which patients should be treated?",
"     </li>",
"     <li>",
"      When should therapy be started?",
"     </li>",
"     <li>",
"      What is the best therapy?",
"     </li>",
"     <li>",
"      How should the disease course and the response to treatment be monitored?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The evaluation, diagnosis, and pathogenesis of IPF are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/23/4474?source=see_link&amp;anchor=H3#H3\">",
"     \"Idiopathic interstitial pneumonias: Clinical manifestations and pathology\", section on 'Usual interstitial pneumonia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/39/32378?source=see_link\">",
"     \"Pathogenesis of idiopathic pulmonary fibrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following observations about the natural history of IPF may be helpful in guiding therapy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Historically, patients with untreated IPF progress; disease progression is usually insidious, at least initially [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/6-8\">",
"       6-8",
"      </a>",
"      ]. Data from the placebo arm of clinical trials suggest that the rate of decline in FVC among untreated patients is 150 to 200 mL per year [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The course of the disease may be unpredictable, as some patients develop an acute deterioration after a period of apparent stability.",
"     </li>",
"     <li>",
"      Patients in the age group affected by IPF (the majority are &gt;55 years old) may have difficulty discerning whether their functional limitations are the result of disease progression, deconditioning, or simply the aging process.",
"     </li>",
"     <li>",
"      Comorbid conditions (eg, COPD, heart failure) may also contribute to symptoms such as cough and reduced exercise tolerance.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GENERAL APPROACH",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important first step is to establish the diagnosis since misdiagnosis can lead to inappropriate initial therapy. High resolution computed tomography (HRCT) may be adequate to establish the diagnosis with a high degree of confidence in a minority of patients with a compatible clinical presentation and no evidence of another contributing process (eg, hypersensitivity pneumonitis, systemic sclerosis, rheumatoid arthritis). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/23/4474?source=see_link&amp;anchor=H3#H3\">",
"     \"Idiopathic interstitial pneumonias: Clinical manifestations and pathology\", section on 'Usual interstitial pneumonia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When the results of HRCT are not classic for IPF, a video-assisted thoracoscopic or open lung biopsy is often necessary. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/23/4474?source=see_link&amp;anchor=H3#H3\">",
"     \"Idiopathic interstitial pneumonias: Clinical manifestations and pathology\", section on 'Usual interstitial pneumonia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/26/424?source=see_link\">",
"     \"Role of lung biopsy in the diagnosis of interstitial lung disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The next step is to stage the patient's severity of disease as this will help to guide treatment choices. Finally, a disease management plan is tailored to the disease severity and desires of the individual patient. Ongoing assessment is needed to refine these choices as the disease progresses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Assessing disease severity",
"    </span>",
"    &nbsp;&mdash;&nbsp;No definitive staging system exists for assessing the severity of IPF, although patients usually progress from mild to moderate to severe respiratory limitation. Disease severity is assessed on the basis of symptoms, HRCT, and pulmonary function testing.",
"   </p>",
"   <p>",
"    Patients with mild or early disease are often asymptomatic or may have a mild, nonproductive cough and dyspnea with substantial exertion. Radiographic changes of reticular opacities and areas of honeycombing are limited to subpleural and basilar areas, involving less than 10 percent of the lung parenchyma. Pulmonary function tests may be normal or may show mild reductions in forced vital capacity (FVC), diffusing capacity (DLCO),",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    distance walked on the six-minute walk test. The alveolar to arterial oxygen gradient (P[A-a]O2) is normal or mildly elevated (&lt;20 mmHg).",
"   </p>",
"   <p>",
"    Moderate disease is characterized by dyspnea on moderate exertion, nonproductive cough, and mild to moderate pulmonary function abnormalities. The latter may include a reduced FVC (eg, 50 to 70 percent of predicted), a reduced DLCO (eg, 45 to 65 percent of predicted)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    P(A-a)O2 (eg, 21 to 30 mmHg). Discordance in the degree of impairment of FVC and DLCO may be noted. Supplemental oxygen may be needed with exertion. Radiographic changes are more extensive with reticular opacities involving 20 to 30 percent of the lung and honeycombing involving of &lt;5 percent of the parenchyma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/10\">",
"     10",
"    </a>",
"    ]. One way of assessing the extent of radiographic changes is to quantitate these radiographic abnormalities on HRCT slices taken at three levels (eg, tracheal carina, inferior pulmonary veins, and 1 cm above the dome of the diaphragm) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Advanced disease is characterized clinically by dyspnea on mild exertion (eg, walking &lt;300 feet or climbing &lt;1 flight of stairs) and requirement for supplemental oxygen at rest",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    with exertion. Extensive honeycombing is noted on HRCT (&gt;5 percent of the parenchyma in three or more zones) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/10\">",
"     10",
"    </a>",
"    ]. Pulmonary function testing typically reveals moderate to severe reductions in the FVC (&lt;50 percent of predicted), DLCO (&lt;50 percent of predicted), and oxygen desaturation (&ge;4 percent) during a six-minute walk test [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/11\">",
"     11",
"    </a>",
"    ]. Gas exchange is also impaired with room air oxygen saturation below 88 percent and P(A-a)O2 difference elevated (&gt;30 mmHg).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Choosing among therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;As no therapy has been proven to be efficacious in this disease, management generally includes some combination of supportive care (eg, supplemental oxygen, pulmonary rehabilitation), consideration for participation in clinical trials, referral for lung transplant evaluation (when appropriate), and identification and treatment of comorbidities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/2,12\">",
"     2,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Education and various components of supportive care should be offered to all patients with IPF. Supportive care may be preferred as the sole treatment option for many patients given the lack of proven therapy. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Supportive care'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Inclusion and exclusion criteria for clinical trials vary, so we provide all patients with information regarding participation in randomized clinical trials whenever appropriate trials are available. Patients with mild to moderate disease are frequently ideal candidates for clinical trials as many limit participation to patients with early disease. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Clinical trials'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Agents such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/26/31141?source=see_link\">",
"     pirfenidone",
"    </a>",
"    show promise, but there is insufficient evidence to recommend their general use at this time. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Pirfenidone'",
"    </a>",
"    below.) Prevention of gastroesophageal reflux and recurrent microaspiration may slow disease progression. (See",
"    <a class=\"local\" href=\"#H34\">",
"     'Future directions'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A number of other agents (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , endothelin receptor antagonists, interferon gamma,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/6/4200?source=see_link\">",
"     penicillamine",
"    </a>",
"    ) have been used in the past either in case series or clinical trials. The agents of doubtful benefit or intolerable toxicity are described below with the evidence against their routine use. (See",
"    <a class=\"local\" href=\"#H39\">",
"     'Other agents'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Ongoing monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ongoing monitoring is used to evaluate the clinical course and identify patients who develop accelerated deterioration. The response to therapy is usually assessed at three to six month intervals. We monitor symptoms (eg, dyspnea, exercise tolerance), forced vital capacity (FVC), total lung capacity (TLC), diffusing capacity (DLCO), and oxygenation at rest and with exercise (eg, oximetry, six-minute walk test) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/11,13-16\">",
"     11,13-16",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Acute exacerbations'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/53/4952?source=see_link\">",
"     \"Overview of pulmonary function testing in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with advanced or progressive disease, careful evaluation for the development of hypoxemia, pulmonary hypertension, thromboembolic disease, or other comorbid conditions (eg, COPD, heart failure, obstructive sleep apnea) may yield additional treatment options [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/2,17\">",
"     2,17",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Supplemental oxygen'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/31/16889?source=see_link\">",
"     \"Pulmonary hypertension associated with interstitial lung disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/22/4456?source=see_link\">",
"     \"Overview of acute pulmonary embolism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/40/41607?source=see_link\">",
"     \"Clinical presentation and diagnosis of obstructive sleep apnea in adults\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H29\">",
"     'Transplantation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SUPPORTIVE CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important components of supportive care for patients with IPF are provision of supplemental oxygen (when needed), education, pulmonary rehabilitation, and vaccination against Streptococcus pneumoniae and influenza.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Supplemental oxygen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Virtually all patients with IPF will eventually require supplemental oxygen, initially just with exertion and then continuously. Oxygen therapy should be prescribed to enable maintenance of normal activity and possibly to prevent or delay the onset of secondary pulmonary hypertension in hypoxemic patients. The indications, benefits, and prescription of supplemental oxygen are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/14/42215?source=see_link\">",
"     \"Long-term supplemental oxygen therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Education",
"    </span>",
"    &nbsp;&mdash;&nbsp;Results from a survey regarding patients' experience with IPF suggest that improved education and communication about the diagnosis and management of IPF are needed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/18\">",
"     18",
"    </a>",
"    ]. For patients with progressive IPF, part of the education should include a discussion of end of life issues and advanced directives. Understanding a patient's individual preferences, beliefs, and values is a key step towards achieving an appropriate management plan [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Pulmonary rehabilitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most of the data that supports the use of pulmonary rehabilitation in the management of patients with chronic respiratory disease comes from the study of COPD. Several studies also support the use of pulmonary rehabilitation in interstitial lung disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/20-24\">",
"     20-24",
"    </a>",
"    ]. As an example, in a series of 113 patients with interstitial lung disease, a significant reduction in dyspnea and improvement in six-minute walk distance were found following participation in a pulmonary rehabilitation program [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38840?source=see_link\">",
"     \"Pulmonary rehabilitation in COPD\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Vaccination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Influenza and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/8/12422?source=see_link\">",
"     pneumococcal polysaccharide vaccine",
"    </a>",
"    should be offered to patients with IPF, as these infections are poorly tolerated in patients with interstitial lung disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/8/37002?source=see_link\">",
"     \"Seasonal influenza vaccination in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/12/21705?source=see_link\">",
"     \"Pneumococcal vaccination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     CLINICAL TRIALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The best hope for patients with IPF is that carefully performed clinical trials will confirm the efficacy and safety of agents that are identified based on animal models of IPF. We encourage appropriate patients to participate in clinical trials of emerging therapies for IPF. Specific trials and registries are available for patients with a familial history of IPF.",
"   </p>",
"   <p>",
"    Clinical trial information is available at",
"    <a class=\"external\" href=\"file://clinicaltrials.gov/\">",
"     Clinicaltrials.gov",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     N-ACETYLCYSTEINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lung injury from excess production of oxidants is thought to be a contributing factor in IPF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/25-31\">",
"     25-31",
"    </a>",
"    ]. This is supported by the observation that bronchoalveolar lavage fluid levels of the antioxidant glutathione are low in patients with IPF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. N-Acetylcysteine (NAC) is a precursor of the antioxidant glutathione, and has been shown to restore depleted glutathione levels in the lung [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/27-30\">",
"     27-30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/39/32378?source=see_link\">",
"     \"Pathogenesis of idiopathic pulmonary fibrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Evidence in favor of using NAC to treat IPF comes from the IFIGENIA (Idiopathic Pulmonary Fibrosis International Group Exploring N-Acetylcysteine I Annual) trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/25\">",
"     25",
"    </a>",
"    ]. When",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"      azathioprine",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"      prednisone",
"     </a>",
"    </span>",
"    plus NAC was compared to",
"    <span class=\"nowrap\">",
"     azathioprine/prednisone/placebo",
"    </span>",
"    in the IFIGENIA trial, the rate of deterioration in vital capacity (-60 versus -190 mL) and single-breath carbon monoxide diffusing capacity (DLCO) (-0.11 versus -0.70",
"    <span class=\"nowrap\">",
"     mmol/min",
"    </span>",
"    per kPa) was lower in the NAC arm. Mortality was not significantly changed (9 versus 11 percent). There were no significant differences in the type or severity of adverse effects.",
"   </p>",
"   <p>",
"    The efficacy of monotherapy with NAC is being examined in the NAC and placebo arms of the multicenter PANTHER trial (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     Prednisone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     Azathioprine",
"    </a>",
"    , and N-acetylcysteine: A Study That Evaluates Response in IPF) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/32,33\">",
"     32,33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Dosage and administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dose of N-acetylcysteine for the treatment of IPF is 1800 mg orally per day (eg, 900 mg administered as effervescent tablets twice daily, 600 mg noneffervescent tablets three times per day). The effervescent formulation, which was used in the IFIGENIA trial above, is not available in the United States; noneffervescent tablets are available, although the relative efficacy is not known. Oral administration of N-acetylcysteine is generally well tolerated. The most common adverse effects include nausea, vomiting, and other gastrointestinal complaints. Rarely, rash with or without fever may occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2359278\">",
"    <span class=\"h1\">",
"     PREDNISONE-AZATHIOPRINE-N-ACETYLCYSTEINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combination therapy with a systemic glucocorticoid and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    has been used for IPF for many years, although supportive clinical trial data was limited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Another combination therapy, systemic glucocorticoid, azathioprine, and the antioxidant N-acetylcysteine&nbsp;(NAC) was assessed in the IFIGENIA (Idiopathic Pulmonary Fibrosis International Group Exploring N-Acetylcysteine&nbsp;I Annual) trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. However, the IFIGENIA trial examined the addition of NAC or placebo to a baseline regimen of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    and azathioprine, rather than comparing the combination regimen to placebo. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'N-Acetylcysteine'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The multicenter PANTHER trial (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     Prednisone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     Azathioprine",
"    </a>",
"    , and N-acetylcysteine: A Study That Evaluates Response in IPF) is a three-armed trial comparing combination therapy (prednisone-azathioprine-NAC), NAC alone, and placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/36\">",
"     36",
"    </a>",
"    ]. In an interim analysis, combination therapy (77 patients) was associated with greater mortality (8 versus 1 deaths), more hospitalizations (23 versus 7), and more serious adverse events (24 versus 8) than placebo (78 patients). Therefore, the combination arm of the trial was stopped; the N-acetylcysteine and placebo arms are ongoing.",
"   </p>",
"   <p>",
"    Based on data from the PANTHER trial, we suggest not initiating combination therapy (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , NAC) in patients with IPF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     PIRFENIDONE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antifibrotic agents are an active area of research because the predominant pathological findings in IPF are fibroblast foci, collagen deposition, and minimal inflammatory cell infiltration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/26/31141?source=see_link\">",
"     Pirfenidone",
"    </a>",
"    (5-methyl-1-phenyl-2-(1H)-pyridone) is an example of an anti-fibrotic agent. In vitro, it inhibits transforming growth factor beta (TGF-b)-stimulated collagen synthesis, decreases the extracellular matrix, and blocks fibroblast proliferation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/39/32378?source=see_link\">",
"     \"Pathogenesis of idiopathic pulmonary fibrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most case series and randomized trials have shown a modest beneficial effect of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/26/31141?source=see_link\">",
"     pirfenidone",
"    </a>",
"    in slowing the progression of IPF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/39-43\">",
"     39-43",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two concurrent, multicenter trials (Clinical studies Assessing",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/26/31141?source=see_link\">",
"       Pirfenidone",
"      </a>",
"      in idiopathic pulmonary fibrosis, CAPACITY 004 and 006) assessed the change in percentage forced vital capacity (FVC) at week 72 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/42\">",
"       42",
"      </a>",
"      ]. Patients with mild-to-moderate IPF (ie, FVC &ge;50 percent predicted and diffusing capacity [DLCO] &ge;35 percent predicted) were randomly assigned to oral pirfenidone 2403",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      1197",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      or placebo in the 004 trial and oral pirfenidone 2403",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      or placebo in the 006 trial. The higher dose of pirfenidone significantly decreased the percent fall in FVC in the 004 trial (difference between groups, 4.4 percent, p=0.001), but not the 006 trial (difference between groups, 0.6 percent, p=0.51). The higher dose of pirfenidone significantly reduced the decline in the 6MWTD, a secondary endpoint, in the 006 (absolute difference 32 meters, p=0.0009), but not the 004 trial.",
"     </li>",
"     <li>",
"      A randomized trial of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/26/31141?source=see_link\">",
"       pirfenidone",
"      </a>",
"      (1800",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      versus placebo was carried out in 107 patients with IPF [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/40\">",
"       40",
"      </a>",
"      ]. The change in the lowest oxygen saturation by pulse oximetry (SpO2) during a six-minute exercise test, the primary endpoint, was not significantly different between the two groups from baseline to six months (+0.6 versus -0.5 percent) and nine months (+0.5 versus -0.9 percent). In a prespecified subset of patients who maintained the SpO2 &gt;80 percent during a six-minute exercise test at baseline, a significant improvement was noted in the pirfenidone group in the lowest SpO2 that occurred during a six-minute exercise test at six months (+0.5 versus -1.9 percent) and nine months (+0.5 versus -1.6 percent), suggesting there may be greater benefit in patients whose disease is less severe.",
"      <br/>",
"      <br/>",
"      In the same trial, a positive treatment effect was demonstrated in secondary endpoints including an increase in vital capacity measurements at nine months (-0.03 versus -0.13 liters) and fewer episodes of acute exacerbation of IPF (14 percent versus none). The trial was aborted in favor of pirfenidone treatment due to the decreased number of acute exacerbations in the pirfenidone group.",
"     </li>",
"     <li>",
"      In a separate multicenter trial, 275 patients were randomly assigned to one of three groups:",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/26/31141?source=see_link\">",
"       pirfenidone",
"      </a>",
"      1800 mg per day, 1200 mg per day, or placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/41\">",
"       41",
"      </a>",
"      ]. The primary endpoint, change in vital capacity (VC), was assessed at 52 weeks; the secondary endpoint was progression free survival. The decline in VC was only slightly less in the high-dose pirfenidone group compared with placebo, but the difference was statistically significant. The progression free survival time was slightly longer in the high dose pirfenidone group compared with placebo.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/26/31141?source=see_link\">",
"     Pirfenidone",
"    </a>",
"    appears to slow the progression of lung impairment in patients with pulmonary fibrosis due to Hermansky-Pudlak syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H175732739\">",
"    <span class=\"h2\">",
"     Dosage and administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/26/31141?source=see_link\">",
"     pirfenidone",
"    </a>",
"    ranges up to 40",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day (to maximum of 2403 mg per day) in three divided doses. This medication is approved for use in patients with mild-to-moderate IPF in Japan, Europe, and Canada, but not in the United States.",
"   </p>",
"   <p>",
"    The most common side effects include rash, photosensitivity, abdominal discomfort, dyspepsia, anorexia, nausea, fatigue, and lethargy. The gastrointestinal side effects may be ameliorated by taking the medication after meals. Other potential side effects include: diarrhea, constipation, itching, dry skin, hyperpigmentation, headache, and weakness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     ACUTE EXACERBATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with IPF may suffer acute deterioration secondary to infections, pulmonary embolism, pneumothorax, or heart failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/12,45\">",
"     12,45",
"    </a>",
"    ]. In addition, the clinical course of IPF is often complicated by \"acute exacerbations\" or an \"accelerated phase of rapid clinical decline\" without an identifiable cause [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/9,45-49\">",
"     9,45-49",
"    </a>",
"    ]. These processes are associated with a poor prognosis.",
"   </p>",
"   <p>",
"    The incidence of these acute exacerbations ranges from 10 to 57 percent, apparently depending on the length of follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/45,49\">",
"     45,49",
"    </a>",
"    ]. The risk factors for acute exacerbations of IPF are unknown. Acute viral infection is unlikely to be a common etiology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/50\">",
"     50",
"    </a>",
"    ]. When lung biopsies have been performed during an episode, the histopathologic pattern of acute lung injury (diffuse alveolar damage) is often found on the background of UIP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Definition",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following criteria for an acute exacerbation of IPF have been proposed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/45\">",
"     45",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Previous or concurrent diagnosis of idiopathic pulmonary fibrosis",
"     </li>",
"     <li>",
"      Unexplained development or worsening of dyspnea within 30 days",
"     </li>",
"     <li>",
"      High-resolution computed tomography with new bilateral ground-glass abnormality",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      consolidation superimposed on a background reticular or honeycomb pattern consistent with usual interstitial pneumonia",
"     </li>",
"     <li>",
"      No evidence of pulmonary infection by endotracheal aspirate or bronchoalveolar lavage",
"     </li>",
"     <li>",
"      Exclusion of alternative causes, including left heart failure, pulmonary embolism, and other identifiable causes of acute lung injury",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients who do not meet all five criteria should be termed \"suspected acute exacerbation.\"",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The key clinical feature is acute or subacute worsening of dyspnea over days to weeks, but generally in less than 30 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/45,51\">",
"     45,51",
"    </a>",
"    ]. Cough, fever, and flu-like symptoms may also be present. Respiratory insufficiency can be severe and require noninvasive support or mechanical ventilation. The most common criteria for impaired gas exchange are an arterial oxygen tension to fraction of inspired oxygen ratio",
"    <span class=\"nowrap\">",
"     (PaO2/FIO2)",
"    </span>",
"    of less than 225 mmHg or a decrease in the PaO2 of 10 mmHg or more from baseline.",
"   </p>",
"   <p>",
"    High resolution CT scans (HRCT) obtained during an acute exacerbation of IPF typically show the underlying fibrotic changes of IPF with new, superimposed alveolar opacities that may be peripheral, multifocal, or diffuse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/51-53\">",
"     51-53",
"    </a>",
"    ]. Among these patterns, prognosis appears to vary; the peripheral pattern may have a better prognosis, multifocal an intermediate prognosis, and diffuse a worse outcome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Implications for practice",
"    </span>",
"    &nbsp;&mdash;&nbsp;After excluding other potential causes of worsening dyspnea and hypoxemia, we typically treat patients who have an acute exacerbation with broad-spectrum antibiotics and high dose glucocorticoids (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day orally or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    1 to 2 g per day intravenously), although scientific evidence for this is lacking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/2,45,54\">",
"     2,45,54",
"    </a>",
"    ]. Some practitioners add a cytotoxic agent such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    or, rarely,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/49,51\">",
"     49,51",
"    </a>",
"    ]. Better understanding and management of these episodes will be critical to reducing the death rate in IPF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mechanical ventilation is often required, but is not usually successful; the hospital mortality rate was 78 percent in one study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/55\">",
"     55",
"    </a>",
"    ]. In patients who survive, a recurrence of acute exacerbation is common and usually results in death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;IPF is the most common interstitial lung disease among referrals for lung transplantation and the second most frequent disease for which lung transplantation is performed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/57,58\">",
"     57,58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Indications and choice of procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with IPF have the highest death rate among the diagnostic groups on the transplant waiting list [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/59\">",
"     59",
"    </a>",
"    ]. For this reason, early referral for transplant evaluation should be considered, even before the response to initial medical therapy has been determined [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/60\">",
"     60",
"    </a>",
"    ]. Under the current United Network for Organ Sharing (UNOS) system, priority for transplantation is determined by medical urgency and expected outcome using a lung allocation score (LAS) (",
"    <a class=\"graphic graphic_table graphicRef59818 \" href=\"mobipreview.htm?40/0/40972\">",
"     table 1",
"    </a>",
"    ). Scores are normalized to a continuous scale from 1 to 100, with higher scores representing higher urgency and greater potential transplant benefit. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/25/3480?source=see_link&amp;anchor=H7#H7\">",
"     \"Lung transplantation: An overview\", section on 'Lung allocation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/29/31192?source=see_link\">",
"     \"Lung transplantation: Disease-based choice of procedure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    General guidelines for transplantation include histologic or radiographic evidence of usual interstitial pneumonia (UIP) and any of the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/61\">",
"     61",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A diffusing capacity (DLCO) &lt;39 percent of predicted",
"     </li>",
"     <li>",
"      A decrement in forced vital capacity (FVC) &gt;10 percent during six months of follow up",
"     </li>",
"     <li>",
"      A decrease in pulse oximetry below 88 percent saturation during a six-minute walk test",
"     </li>",
"     <li>",
"      Honeycombing on high resolution chest tomography (HRCT) (fibrosis score &gt;2 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/62\">",
"       62",
"      </a>",
"      ])",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among 1256 patients transplanted between May 2005 and December 2007, the one year survival rate was 74 percent among those with scores in the highest lung allocation quartile (LAS 52.0 to 94.1) and 84 percent among those in the lowest lung allocation score quartile (LAS 31.1 to 37.8) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/63\">",
"     63",
"    </a>",
"    ]. Evaluation of the LAS factors predicting mortality revealed that IPF patients being ventilated before transplantation had an increased risk of mortality at one year (HR, 3.78; 95% CI, 2.32 to 6.17) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/63\">",
"     63",
"    </a>",
"    ]. The five-year survival rate for lung transplantation in IPF is 40 to 50 percent, compared with a five-year survival rate of 52 percent for all lung transplant recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/58,64-66\">",
"     58,64-66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although single lung transplantation (SLT) has been the standard procedure for IPF, bilateral lung transplant (BLT) may prove to have better long-term survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/64,65,67-72\">",
"     64,65,67-72",
"    </a>",
"    ]. Mild to moderate secondary pulmonary hypertension preoperatively increased the risk of reperfusion injury in one study, but did not appear to affect survival in two retrospective studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/73,74\">",
"     73,74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Following SLT, the low lung compliance and high vascular resistance of the remaining native lung preferentially direct both ventilation and perfusion to the transplanted lung. Cysts, bullae, and bronchiectasis that occasionally develop in the later stages of IPF can act as a nidus for infectious complications after SLT; when these are identified, BLT may be preferred.",
"   </p>",
"   <p>",
"    Early experience suggests that living donor lobar lung transplantation (LDLLT) may be an option for patients with IPF who are likely to die while waiting for SLT. In a report of nine such patients, eight of whom were dependent on systemic glucocorticoids (up to 50",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    only one early death occurred after transplant of two lower lobes donated by two healthy relatives [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/75\">",
"     75",
"    </a>",
"    ]. Eight patients were still alive after 10 to 48 months of follow-up.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Physiologic changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;After SLT or BLT, spirometric parameters, lung volumes, diffusing capacity, and oxygenation improve significantly, and these improvements have been sustained in long-term follow-up of recipients without complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/67-70\">",
"     67-70",
"    </a>",
"    ]. In a series that compared SLT and BLT recipients with IPF, the mean FEV1 was higher in BLT recipients than SLT recipients one year after transplantation (2.25 versus 2.00 liters) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After SLT, most lung function is contributed by the allograft. As a result, the vital capacity (VC) of the recipient correlates closely with the predicted vital capacity of the donor organ [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/76\">",
"     76",
"    </a>",
"    ]. Improvements in cardiopulmonary function continue for up to one year following transplantation. As an example, in one study of SLT recipients, the mean VC increased from 43 percent of the predicted normal value preoperatively to 65 percent three months and 69 percent one year after transplantation. None of the eight recipients tested one year after transplantation required supplemental oxygen at rest or during exercise, and their treadmill exercise tolerance was much improved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Prior treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of prior glucocorticoid therapy on the outcome of lung transplantation is uncertain. Most studies suggest that low-dose glucocorticoid therapy has no adverse effect on outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/77-79\">",
"     77-79",
"    </a>",
"    ]. However, high-dose glucocorticoid therapy may be associated with decreased survival after lung transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/79\">",
"     79",
"    </a>",
"    ]. The International Guidelines for the Selection of Lung Transplant Candidates lists",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    use &gt;20",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    as a relative contraindication for lung transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/61\">",
"     61",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/20/26953?source=see_link&amp;anchor=H11#H11\">",
"     \"Lung transplantation: General guidelines for recipient selection\", section on 'Glucocorticoid use'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis of IPF is poor, with only 20 to 30 percent of subjects alive five years after diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/4,5,7,80-84\">",
"     4,5,7,80-84",
"    </a>",
"    ]. Several factors have been associated with shortened survival time: older age at presentation, extensive cigarette smoking, lower body mass index (BMI), more severe physiologic impairment, greater radiologic extent of disease, and the development of other complications or conditions, eg, pulmonary hypertension, emphysema, and bronchogenic cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/13,85-91\">",
"     13,85-91",
"    </a>",
"    ]. Co-morbid diseases and adverse effects of therapy also contribute (",
"    <a class=\"graphic graphic_table graphicRef75965 \" href=\"mobipreview.htm?40/23/41339\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/87,92\">",
"     87,92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical deterioration is most frequently due to disease progression. Data from the placebo arms of recent randomized clinical trials show that the mean rate of decline in forced vital capacity (FVC) is approximately 150 to 200",
"    <span class=\"nowrap\">",
"     mL/yr",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hospitalizations for respiratory problems are common events and are frequently associated with death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/9,93\">",
"     9,93",
"    </a>",
"    ]. Patients with IPF admitted to intensive care units are at greater risk of mortality than expected based on their severity of illness, as assessed by the APACHE score [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/56,87\">",
"     56,87",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/56/27527?source=see_link&amp;anchor=H5#H5\">",
"     \"Predictive scoring systems in the intensive care unit\", section on 'Acute Physiologic and Chronic Health Evaluation (APACHE)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     FUTURE DIRECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The agents currently available for the treatment of IPF are clearly inadequate. Therapeutic response is obtained in only a subset of patients, and survival is poor even for those who respond. In addition, these agents all carry significant side effects and toxicity. For these reasons, there is much interest in developing more effective, less toxic pharmacologic therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/94,95\">",
"     94,95",
"    </a>",
"    ]. Some examples of potential future therapies are provided in the following sections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4990318\">",
"    <span class=\"h2\">",
"     Thalidomide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     Thalidomide",
"    </a>",
"    is an immune modulator and anti-fibrotic agent that ameliorates bleomycin-induced pulmonary fibrosis in mice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/96\">",
"     96",
"    </a>",
"    ]. The effect of thalidomide on cough, a debilitating symptom in IPF, was assessed in 23 patients with IPF who were randomly assigned to thalidomide or placebo in a 24 week crossover trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/97\">",
"     97",
"    </a>",
"    ]. Twenty-two participants completed 12 weeks of the placebo regimen, and 20 completed 12 weeks of thalidomide. The primary endpoint, improvement in the Cough Quality of Life Questionnaire (CQLQ), favored thalidomide (mean difference versus placebo, -11.4 [95% CI, -15.7 to -7.0]). Cough severity measured on a visual analog scale also improved. Adverse events attributed to thalidomide included constipation (36 percent), dizziness (27 percent), malaise 14 percent, anorexia (5 percent) and asymptomatic bradycardia (5 percent). The potential benefit of thalidomide in IPF will need validation in a larger and longer multicenter trial that assesses additional endpoints, such as mortality and lung function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28340207\">",
"    <span class=\"h2\">",
"     Tyrosine kinase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several of the fibrogenic growth factors that appear to participate in IPF (eg, platelet-derived growth factor, vascular endothelial growth factor, fibroblast growth factor) act via tyrosine kinase receptors, raising the possibility that inhibition of these receptors would slow the rate of disease progression. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/39/32378?source=see_link&amp;anchor=H12#H12\">",
"     \"Pathogenesis of idiopathic pulmonary fibrosis\", section on 'Cytokines, growth factors, and other molecules'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The efficacy of the tyrosine kinase inhibitor BIBF 1120 (nintedanib) was assessed as a treatment for IPF in a phase 2 trial (To Improve Pulmonary Fibrosis with BIBF 1120) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/98\">",
"     98",
"    </a>",
"    ]. A total of 432 patients were randomly assigned to one of four oral doses of BIBF 1120 or placebo. The group taking the highest dose of BIBF 1120, 150 mg twice daily, showed a trend towards a slower decline in lung function and fewer exacerbations compared with placebo. However, the methodologic problems related to the multiple doses of study medication may have reduced the likelihood of a positive result; improvements were noted in several of the secondary endpoints.",
"   </p>",
"   <p>",
"    Another tyrosine kinase inhibitor,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    , inhibits a narrower spectrum of growth factors and had no effect on survival or lung function in IPF, when compared with placebo. (See",
"    <a class=\"local\" href=\"#H42\">",
"     'Imatinib'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Immunomodulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there is still much to be learned regarding the roles of various cytokines and growth factors in the complex process of pulmonary fibrosis, it is clear that these agents are critical [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/94,95\">",
"     94,95",
"    </a>",
"    ]. Inhibitors of specific fibrogenic cytokines or growth factors (eg, tumor necrosis factor alpha antagonists, interleukin 1 receptor antagonist [IL-1ra], anti-CD 11 antibody) may help to retard the fibrotic process [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/99-101\">",
"     99-101",
"    </a>",
"    ]. Although these agents may appear to be effective in animal models of pulmonary fibrosis, it will be important to evaluate them fully in randomized, placebo-controlled trials in humans.",
"   </p>",
"   <p>",
"    Another potential strategy involves interfering with the process of leukocyte retention in the lung [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/94\">",
"     94",
"    </a>",
"    ]. Leukocyte adhesion molecules play an important role in this process, and antibodies to such adhesion molecules have been shown to prevent collagen deposition in an animal model of lung injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/102\">",
"     102",
"    </a>",
"    ]. Agents that block the expression or function of adhesion molecules are rapidly becoming available and may someday prove clinically useful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Gastroesophageal reflux and chronic microaspiration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Up to 90 percent of patients with IPF have gastroesophageal reflux (GER) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/103-105\">",
"     103-105",
"    </a>",
"    ]. It has been hypothesized that GER is an important risk factor for the development",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    progression of IPF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/106-110\">",
"     106-110",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a systematic review, it was noted that 67 to 76 percent of patients with IPF assessed with ambulatory pH probe monitoring had abnormal distal esophageal acid exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/111\">",
"     111",
"    </a>",
"    ]. In addition, classic symptoms of GER (heartburn, acid regurgitation) were poor predictors of increased esophageal acid exposure among patients with moderate to severe IPF. In a separate study, reflux in patients with IPF was associated with a hypotensive lower esophageal sphincter and abnormal esophageal peristalsis, and often extended into the proximal esophagus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/112\">",
"     112",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effect of anti-GER treatment on IPF disease progression has also been examined. A retrospective study of 204 patients with IPF found that reported use of anti-GER medications was associated with decreased radiographic fibrosis scores on chest computed tomography and was an independent predictor of longer survival time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/113\">",
"     113",
"    </a>",
"    ]. These observations suggest that the treatment of GER may prove to be an important adjunct in the management of IPF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Phosphodiesterase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;As IPF progresses, a substantial portion of patients develop pulmonary hypertension. This has led to the hypothesis that treating IPF-related pulmonary hypertension with a phosphodiesterase inhibitor might improve exercise tolerance, as in idiopathic pulmonary hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/114-116\">",
"     114-116",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/24/35210?source=see_link&amp;anchor=H29#H29\">",
"     \"Treatment of pulmonary hypertension in adults\", section on 'PDE5 inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a randomized trial, 180 patients with advanced IPF (defined as a diffusing capacity less than 35 percent of predicted) were assigned to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    20 mg three times daily or placebo for 12 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/116\">",
"     116",
"    </a>",
"    ]. Exclusion criteria included a six-minute walk distance less than 50 m (164 feet), treatment with medications containing nitrates, and presence of aortic stenosis or hypertrophic subaortic stenosis. No difference was found in the primary end-point of at least a 20 percent improvement in the six-minute walk distance compared with baseline. Small differences were noted between the groups in dyspnea and quality of life, favoring sildenafil.",
"   </p>",
"   <p>",
"    A separate open-label observational study of patients with IPF and PAH found that treatment with the phosphodiesterase inhibitor",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    resulted in a modest improvement in six-minute walk with a mean increase in distance walked of 49 meters, which is lower than the usual standard of 54 m for a clinically important increase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/114\">",
"     114",
"    </a>",
"    ]. However, a subsequent randomized trial of 29 subjects found no significant difference in the six-minute walk with sildenafil compared with placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/115\">",
"     115",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Further trials of longer duration are needed to determine the safety and efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    in the treatment of IPF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h1\">",
"     OTHER AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of agents have been evaluated for use in IPF, but are not currently used for this indication. The following agents are mentioned here to provide clinicians with an overview of the evidence for and against their use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86165214\">",
"    <span class=\"h2\">",
"     Anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been proposed that a prothrombotic state exists in patients with IPF that may contribute to mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/117,118\">",
"     117,118",
"    </a>",
"    ]. The hypothesis that anticoagulation might reduce mortality in IPF was initially tested in a nonblinded trial of 56 IPF patients who were hospitalized due to worsening dyspnea; subjects were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    PLUS long-term anticoagulation or prednisolone alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/119\">",
"     119",
"    </a>",
"    ]. A significant improvement in survival was found at three years in the anticoagulant group (63 versus 35 percent).",
"   </p>",
"   <p>",
"    However, due to methodologic concerns with the above study, the Anticoagulant Effectiveness in Idiopathic Pulmonary Fibrosis trial (ACE-IPF; NCT00957242), was performed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/12,120,121\">",
"     12,120,121",
"    </a>",
"    ]. In the ACE-IPF trial, 145 subjects with IPF but without other indications for anticoagulation were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    anticoagulation (to an International Normalized Ratio [INR] of 2.0 to 3.0) or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/121\">",
"     121",
"    </a>",
"    ]. After a mean follow-up of 28 weeks, the study was stopped due to an increase in mortality in the subjects randomized to warfarin (14 warfarin versus 3 placebo deaths; P = 0.005) and a low probability of benefit. None of the deaths was attributed to bleeding complications.",
"   </p>",
"   <p>",
"    Anticoagulation with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    is not indicated in patients with IPF who lack other indications for anticoagulation, due to the increased risk of mortality. However, anticoagulation should not be withheld from patients with IPF who have other indications for anticoagulation based on this trial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Colchicine",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest not using",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    in the treatment of IPF because evidence of efficacy is lacking. There have been numerous in vitro and animal model studies suggesting that colchicine may slow the fibrotic process [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/122-125\">",
"     122-125",
"    </a>",
"    ]. However, several clinical studies, including retrospective studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/85,126\">",
"     85,126",
"    </a>",
"    ], a randomized trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/86\">",
"     86",
"    </a>",
"    ], and a nonrandomized prospective study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/127\">",
"     127",
"    </a>",
"    ], failed to show a significant difference in the rate of decline of lung function when patients were treated with colchicine or glucocorticoids.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Cyclophosphamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;We rarely use",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    (Cytoxan) because of its toxicity and lack of proven benefit. Although several small series suggested that cyclophosphamide (usually given along with low doses of glucocorticoids) might be beneficial in the treatment of IPF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/128-130\">",
"     128-130",
"    </a>",
"    ], one of the largest retrospective series found no survival benefit among 82 patients on the combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    and oral cyclophosphamide compared with 82 on prednisone alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/131\">",
"     131",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    only be used to treat IPF when there has been a clinical impression of response to immunosuppressive treatment, but the combination of glucocorticoid,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , and N-acetylcysteine has not been tolerated.",
"   </p>",
"   <p>",
"    Dosing and treatment considerations for the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/40/16008?source=see_link\">",
"     \"General principles of the use of cyclophosphamide in rheumatic and renal disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/32/25098?source=see_link\">",
"     \"General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2359946\">",
"    <span class=\"h2\">",
"     Endothelin receptor antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several trials examining the efficacy of endothelin receptor antagonists in IPF failed to meet their primary objectives and are not being used in IPF treatment.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/16/40200?source=see_link\">",
"     Bosentan",
"    </a>",
"    (Tracleer), a nonselective endothelin receptor antagonist, was evaluated as a therapy for IPF because of its antifibrotic properties [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/132\">",
"     132",
"    </a>",
"    ]. In the multicenter trial BUILD 1 (Efficacy and Safety of Oral Bosentan in Patients With Idiopathic Pulmonary Fibrosis), there was no significant difference in the primary endpoint of exercise capacity, as measured by a six-minute walk, or in the secondary endpoints of dyspnea and quality of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/133,134\">",
"     133,134",
"    </a>",
"    ]. A follow-up study, the multinational BUILD 3 trial (Bosentan Use in Interstitial Lung Disease 3), was designed to examine the trend toward delayed time to death or disease progression observed in BUILD 1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/133,135\">",
"     133,135",
"    </a>",
"    ]. However, it did not meet its primary end-point of time to IPF worsening or death.",
"   </p>",
"   <p>",
"    An additional multinational trial examining the role of macitentan, a highly potent, tissue-targeting endothelin receptor antagonist in early IPF failed to meet the primary endpoint (Macitentan Use in an IPF Clinical Study or &ldquo;MUSIC&rdquo; trial; clinical trials identifier: NCT00903331 at",
"    <a class=\"external\" href=\"file://clinicaltrials.gov/\">",
"     Clinicaltrials.gov",
"    </a>",
"    ). The \"ARTEMIS-IPF Trial\" (Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/60/29637?source=see_link\">",
"     Ambrisentan",
"    </a>",
"    in IPF; clinical trials identifier: NCT00768300) of ambrisentan, a type A endothelin receptor antagonist, was terminated due to lack of efficacy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h2\">",
"     Imatinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     Imatinib",
"    </a>",
"    mesylate is a tyrosine kinase inhibitor with activity against the platelet-derived growth factor receptors (PDGFRs), c-kit, and c-Abl. As PDGFR has been implicated in the pathogenesis of IPF, imatinib was evaluated as a possible therapy. In a 96 week trial, 119 patients with mild to moderate IPF were randomly assigned to receive imatinib or placebo 600 mg once daily [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/136\">",
"     136",
"    </a>",
"    ]. Imatinib had no effect on survival or lung function, when compared with placebo.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h2\">",
"     Interferon gamma-1b",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rationale for the use of subcutaneous interferon gamma (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20308?source=see_link\">",
"     interferon gamma-1b",
"    </a>",
"    ) in IPF came, in part, from the hypothesis that an acquired deficiency of interferon gamma exists in IPF and may contribute to the exaggerated wound healing process characteristic of this disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/137-139\">",
"     137-139",
"    </a>",
"    ]. A placebo-controlled, randomized trial suggested a possible mortality benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/122\">",
"     122",
"    </a>",
"    ], but a subsequent large multinational trial was halted when the primary end point of a mortality benefit was not achieved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/140\">",
"     140",
"    </a>",
"    ]. We recommend not using subcutaneous interferon gamma-1b to treat IPF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h2\">",
"     Methotrexate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    , an analogue of the vitamin",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    , inhibits cellular proliferation by inducing an acute intracellular deficiency of certain folate coenzymes. It has both antineoplastic and immunosuppressive effects. There have been several descriptions of using methotrexate in sarcoidosis, but very little has been written regarding its effectiveness in IPF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/141-144\">",
"     141-144",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In general, we do not use",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    to treat patients with IPF because of the lack of data demonstrating benefit and concern about methotrexate-induced pneumonitis. In patients with IPF, it may be difficult to distinguish pulmonary drug toxicity from progression of the underlying disease.",
"   </p>",
"   <p>",
"    Interstitial lung disease in the context of autoimmune disease (eg, rheumatoid arthritis) may have a significant component of usual interstitial pneumonitis based on radiographic and histologic assessment. In this situation,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    may be of benefit. As an example, one study described three patients with IPF associated with connective tissue disease who appeared to respond favorably to methotrexate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/145\">",
"     145",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of low dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    is described separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/26/32169?source=see_link\">",
"     \"Use of methotrexate in the treatment of rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11223?source=see_link\">",
"     \"Major side effects of low-dose methotrexate\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/5/9306?source=see_link\">",
"     \"Methotrexate-induced lung injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h2\">",
"     Cyclosporine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Experience with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    for the treatment of IPF is limited; we do not prescribe cyclosporine in patients with IPF because of the high toxicity and absence of proven benefit. The few published reports have been anecdotal and less than encouraging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/146-149\">",
"     146-149",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h2\">",
"     Etanercept",
"    </span>",
"    &nbsp;&mdash;&nbsp;Animal models of pulmonary fibrosis have suggested that antagonists of tumor necrosis factor (TNF)-alpha might be effective in treating IPF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/99\">",
"     99",
"    </a>",
"    ]. The efficacy and safety of the TNF-alpha receptor blocker,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    , were evaluated in a trial that randomly assigned 88 patients to twice weekly subcutaneous etanercept or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/150\">",
"     150",
"    </a>",
"    ]. After 48 weeks, no significant difference was seen in the primary endpoints of change in percent predicted FVC or DLCO, or in the arterial-alveolar oxygen gradient. Given the potential side effects and lack of proven efficacy, we recommend that etanercept NOT be used to treat IPF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h2\">",
"     Penicillamine",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest not using d-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/6/4200?source=see_link\">",
"     penicillamine",
"    </a>",
"    as a treatment for IPF because evidence of efficacy is lacking.",
"   </p>",
"   <p>",
"    D-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/6/4200?source=see_link\">",
"     penicillamine",
"    </a>",
"    is capable of affecting collagen biosynthesis and the immune system. Several animal studies suggested a possible role for penicillamine in the treatment of fibrotic lung disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/151-154\">",
"     151-154",
"    </a>",
"    ]. In addition, two retrospective studies of patients with fibrosing alveolitis associated with scleroderma reported that penicillamine therapy was associated with an improvement in DLCO (but not in other pulmonary function test parameters) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/155,156\">",
"     155,156",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Experience with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/6/4200?source=see_link\">",
"     penicillamine",
"    </a>",
"    in patients with IPF is limited and not encouraging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/127,157,158\">",
"     127,157,158",
"    </a>",
"    ]. A nonrandomized prospective study in patients with IPF compared",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?32/13/32983?source=see_link\">",
"      colchicine",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"      prednisone",
"     </a>",
"    </span>",
"    (n = 19),",
"    <span class=\"nowrap\">",
"     D-penicillamine/prednisone",
"    </span>",
"    (n = 11),",
"    <span class=\"nowrap\">",
"     D-penicillamine/colchicine/prednisone",
"    </span>",
"    (n = 11), and prednisone alone (n = 15). No significant differences in survival or in lung function relative to the baseline measurement were found in any group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/60/34762/abstract/127\">",
"     127",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?7/31/7666?source=see_link\">",
"       \"Patient information: Idiopathic pulmonary fibrosis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sufficient clinical evidence that any treatment improves survival or quality of life for patients with idiopathic pulmonary fibrosis (IPF) is lacking. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'General approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We offer supportive care (eg, supplemental oxygen, pulmonary rehabilitation) and provide information regarding participation in randomized trials to all patients. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'General approach'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Supportive care'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Clinical trials'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      N-Acetylcysteine (NAC) is an antioxidant agent. For patients who desire active therapy rather than supportive care alone and are not interested in participating in a clinical trial, we suggest oral N-acetylcysteine (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The usual dose is 1800 mg orally per day (eg, 900 mg administered as effervescent tablets twice daily, 600 mg noneffervescent tablets three times per day). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'N-Acetylcysteine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Alternatively, for patients who desire active therapy rather than supportive care alone, are not interested in participating in a clinical trial, and live in an area where",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/26/31141?source=see_link\">",
"       pirfenidone",
"      </a>",
"      is available, we suggest administering pirfenidone (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The dose ranges up to 40",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day (to maximum of 2403 mg per day) in three divided doses. Rash, photosensitivity, dyspepsia, and nausea are common side effects. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Pirfenidone'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest NOT using glucocorticoid monotherapy for treatment of IPF (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). In addition, we suggest NOT using combination therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      , and N-acetylcysteine for routine therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2359278\">",
"       'Prednisone-Azathioprine-N-Acetylcysteine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lung transplantation may be an option for patients with progressive disease and minimal comorbidities. For appropriate patients (based on criteria from the United Network for Organ Sharing [UNOS]), we suggest early referral for lung transplantation evaluation rather than waiting until the patient has developed advanced disease (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Transplantation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with an acute exacerbation of IPF, we typically administer broad-spectrum antibiotics and high dose glucocorticoids in combination with a cytotoxic agent such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      , although data to support this practice is lacking. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Acute exacerbations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2359278\">",
"       'Prednisone-Azathioprine-N-Acetylcysteine'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/1\">",
"      Lynch DA, Godwin JD, Safrin S, et al. High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. Am J Respir Crit Care Med 2005; 172:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/2\">",
"      Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/3\">",
"      King TE Jr, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet 2011; 378:1949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/4\">",
"      Schwartz DA, Helmers RA, Galvin JR, et al. Determinants of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1994; 149:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/5\">",
"      Schwartz DA, Van Fossen DS, Davis CS, et al. Determinants of progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1994; 149:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/6\">",
"      Flaherty KR, Toews GB, Lynch JP 3rd, et al. Steroids in idiopathic pulmonary fibrosis: a prospective assessment of adverse reactions, response to therapy, and survival. Am J Med 2001; 110:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/7\">",
"      Carrington CB, Gaensler EA, Coutu RE, et al. Natural history and treated course of usual and desquamative interstitial pneumonia. N Engl J Med 1978; 298:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/8\">",
"      Wright PH, Heard BE, Steel SJ, Turner-Warwick M. Cryptogenic fibrosing alveolitis: assessment by graded trephine lung biopsy histology compared with clinical, radiographic, and physiological features. Br J Dis Chest 1981; 75:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/9\">",
"      Martinez FJ, Safrin S, Weycker D, et al. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med 2005; 142:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/10\">",
"      Arakawa H, Honma K. Honeycomb lung: history and current concepts. AJR Am J Roentgenol 2011; 196:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/11\">",
"      Lama VN, Flaherty KR, Toews GB, et al. Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003; 168:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/12\">",
"      Walter N, Collard HR, King TE Jr. Current perspectives on the treatment of idiopathic pulmonary fibrosis. Proc Am Thorac Soc 2006; 3:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/13\">",
"      King TE Jr, Tooze JA, Schwarz MI, et al. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med 2001; 164:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/14\">",
"      King TE Jr, Safrin S, Starko KM, et al. Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis. Chest 2005; 127:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/15\">",
"      Nishiyama O, Taniguchi H, Kondoh Y, et al. A simple assessment of dyspnoea as a prognostic indicator in idiopathic pulmonary fibrosis. Eur Respir J 2010; 36:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/16\">",
"      du Bois RM, Weycker D, Albera C, et al. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med 2011; 184:1382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/17\">",
"      Lancaster LH, Mason WR, Parnell JA, et al. Obstructive sleep apnea is common in idiopathic pulmonary fibrosis. Chest 2009; 136:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/18\">",
"      Collard HR, Tino G, Noble PW, et al. Patient experiences with pulmonary fibrosis. Respir Med 2007; 101:1350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/19\">",
"      Daniels CE, Ryu JH. Treatment of idiopathic pulmonary fibrosis. Semin Respir Crit Care Med 2006; 27:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/20\">",
"      Holland AE, Hill CJ, Conron M, et al. Short term improvement in exercise capacity and symptoms following exercise training in interstitial lung disease. Thorax 2008; 63:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/21\">",
"      Ferreira A, Garvey C, Connors GL, et al. Pulmonary rehabilitation in interstitial lung disease: benefits and predictors of response. Chest 2009; 135:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/22\">",
"      Nishiyama O, Kondoh Y, Kimura T, et al. Effects of pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis. Respirology 2008; 13:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/23\">",
"      Salhi B, Troosters T, Behaegel M, et al. Effects of pulmonary rehabilitation in patients with restrictive lung diseases. Chest 2010; 137:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/24\">",
"      Kozu R, Senjyu H, Jenkins SC, et al. Differences in response to pulmonary rehabilitation in idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease. Respiration 2011; 81:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/25\">",
"      Demedts M, Behr J, Buhl R, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005; 353:2229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/26\">",
"      Cantin AM, North SL, Fells GA, et al. Oxidant-mediated epithelial cell injury in idiopathic pulmonary fibrosis. J Clin Invest 1987; 79:1665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/27\">",
"      Meyer A, Buhl R, Magnussen H. The effect of oral N-acetylcysteine on lung glutathione levels in idiopathic pulmonary fibrosis. Eur Respir J 1994; 7:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/28\">",
"      Meyer A, Buhl R, Kampf S, Magnussen H. Intravenous N-acetylcysteine and lung glutathione of patients with pulmonary fibrosis and normals. Am J Respir Crit Care Med 1995; 152:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/29\">",
"      Behr J, Maier K, Degenkolb B, et al. Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis. Adjunctive therapy to maintenance immunosuppression. Am J Respir Crit Care Med 1997; 156:1897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/30\">",
"      Behr J, Degenkolb B, Krombach F, Vogelmeier C. Intracellular glutathione and bronchoalveolar cells in fibrosing alveolitis: effects of N-acetylcysteine. Eur Respir J 2002; 19:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/31\">",
"      Cantin AM, Hubbard RC, Crystal RG. Glutathione deficiency in the epithelial lining fluid of the lower respiratory tract in idiopathic pulmonary fibrosis. Am Rev Respir Dis 1989; 139:370.",
"     </a>",
"    </li>",
"    <li>",
"     Commonly used three-drug regimen for idiopathic pulmonary fibrosis found harmful. NIH News October 21, 2011. file://www.nih.gov/news/health/oct2011/nhlbi-21.htm (Accessed on January 06, 2012).",
"    </li>",
"    <li>",
"     Evaluating the Effectiveness of Prednisone, Azathioprine, and N-acetylcysteine in People With Idiopathic Pulmonary Fibrosis (PANTHER-IPF) file://clinicaltrials.gov/ct2/show/study/NCT00650091?term=panther&amp;rank=4 (Accessed on January 06, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/34\">",
"      Davies HR, Richeldi L, Walters EH. Immunomodulatory agents for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev 2003; :CD003134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/35\">",
"      Raghu G, Depaso WJ, Cain K, et al. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. Am Rev Respir Dis 1991; 144:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/36\">",
"      Idiopathic Pulmonary Fibrosis Clinical Research Network, Raghu G, Anstrom KJ, et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012; 366:1968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/37\">",
"      Hunninghake GW, Kalica AR. Approaches to the treatment of pulmonary fibrosis. Am J Respir Crit Care Med 1995; 151:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/38\">",
"      Scotton CJ, Chambers RC. Molecular targets in pulmonary fibrosis: the myofibroblast in focus. Chest 2007; 132:1311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/39\">",
"      Raghu G, Johnson WC, Lockhart D, Mageto Y. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study. Am J Respir Crit Care Med 1999; 159:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/40\">",
"      Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005; 171:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/41\">",
"      Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010; 35:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/42\">",
"      Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011; 377:1760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/43\">",
"      Spagnolo P, Del Giovane C, Luppi F, et al. Non-steroid agents for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev 2010; :CD003134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/44\">",
"      Gahl WA, Brantly M, Troendle J, et al. Effect of pirfenidone on the pulmonary fibrosis of Hermansky-Pudlak syndrome. Mol Genet Metab 2002; 76:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/45\">",
"      Collard HR, Moore BB, Flaherty KR, et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2007; 176:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/46\">",
"      Kondoh Y, Taniguchi H, Kawabata Y, et al. Acute exacerbation in idiopathic pulmonary fibrosis. Analysis of clinical and pathologic findings in three cases. Chest 1993; 103:1808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/47\">",
"      Ambrosini V, Cancellieri A, Chilosi M, et al. Acute exacerbation of idiopathic pulmonary fibrosis: report of a series. Eur Respir J 2003; 22:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/48\">",
"      Churg A, Wright JL, Tazelaar HD. Acute exacerbations of fibrotic interstitial lung disease. Histopathology 2011; 58:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/49\">",
"      Song JW, Hong SB, Lim CM, et al. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J 2011; 37:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/50\">",
"      Wootton SC, Kim DS, Kondoh Y, et al. Viral infection in acute exacerbation of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 183:1698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/51\">",
"      Simon-Blancal V, Freynet O, Nunes H, et al. Acute exacerbation of idiopathic pulmonary fibrosis: outcome and prognostic factors. Respiration 2012; 83:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/52\">",
"      Akira M, Kozuka T, Yamamoto S, Sakatani M. Computed tomography findings in acute exacerbation of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008; 178:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/53\">",
"      Tcherakian C, Cottin V, Brillet PY, et al. Progression of idiopathic pulmonary fibrosis: lessons from asymmetrical disease. Thorax 2011; 66:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/54\">",
"      Hyzy R, Huang S, Myers J, et al. Acute exacerbation of idiopathic pulmonary fibrosis. Chest 2007; 132:1652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/55\">",
"      Kim DS, Park JH, Park BK, et al. Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features. Eur Respir J 2006; 27:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/56\">",
"      Saydain G, Islam A, Afessa B, et al. Outcome of patients with idiopathic pulmonary fibrosis admitted to the intensive care unit. Am J Respir Crit Care Med 2002; 166:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/57\">",
"      Alalawi R, Whelan T, Bajwa RS, Hodges TN. Lung transplantation and interstitial lung disease. Curr Opin Pulm Med 2005; 11:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/58\">",
"      Christie JD, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: Twenty-eighth Adult Lung and Heart-Lung Transplant Report--2011. J Heart Lung Transplant 2011; 30:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/59\">",
"      Thabut G, Mal H, Castier Y, et al. Survival benefit of lung transplantation for patients with idiopathic pulmonary fibrosis. J Thorac Cardiovasc Surg 2003; 126:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/60\">",
"      Steinman TI, Becker BN, Frost AE, et al. Guidelines for the referral and management of patients eligible for solid organ transplantation. Transplantation 2001; 71:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/61\">",
"      Orens JB, Estenne M, Arcasoy S, et al. International guidelines for the selection of lung transplant candidates: 2006 update--a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2006; 25:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/62\">",
"      Kazerooni EA, Martinez FJ, Flint A, et al. Thin-section CT obtained at 10-mm increments versus limited three-level thin-section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring. AJR Am J Roentgenol 1997; 169:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/63\">",
"      Weiss ES, Allen JG, Merlo CA, et al. Lung allocation score predicts survival in lung transplantation patients with pulmonary fibrosis. Ann Thorac Surg 2009; 88:1757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/64\">",
"      Christie JD, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: 29th adult lung and heart-lung transplant report-2012. J Heart Lung Transplant 2012; 31:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/65\">",
"      Mason DP, Brizzio ME, Alster JM, et al. Lung transplantation for idiopathic pulmonary fibrosis. Ann Thorac Surg 2007; 84:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/66\">",
"      George TJ, Arnaoutakis GJ, Shah AS. Lung transplant in idiopathic pulmonary fibrosis. Arch Surg 2011; 146:1204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/67\">",
"      Unilateral lung transplantation for pulmonary fibrosis. Toronto Lung Transplant Group. N Engl J Med 1986; 314:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/68\">",
"      Experience with single-lung transplantation for pulmonary fibrosis. The Toronto Lung Transplant Group. JAMA 1988; 259:2258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/69\">",
"      Grossman RF, Frost A, Zamel N, et al. Results of single-lung transplantation for bilateral pulmonary fibrosis. The Toronto Lung Transplant Group. N Engl J Med 1990; 322:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/70\">",
"      Meyers BF, Lynch JP, Trulock EP, et al. Single versus bilateral lung transplantation for idiopathic pulmonary fibrosis: a ten-year institutional experience. J Thorac Cardiovasc Surg 2000; 120:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/71\">",
"      Meyer DM, Edwards LB, Torres F, et al. Impact of recipient age and procedure type on survival after lung transplantation for pulmonary fibrosis. Ann Thorac Surg 2005; 79:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/72\">",
"      Neurohr C, Huppmann P, Thum D, et al. Potential functional and survival benefit of double over single lung transplantation for selected patients with idiopathic pulmonary fibrosis. Transpl Int 2010; 23:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/73\">",
"      Fitton TP, Kosowski TR, Barreiro CJ, et al. Impact of secondary pulmonary hypertension on lung transplant outcome. J Heart Lung Transplant 2005; 24:1254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/74\">",
"      Nathan SD, Shlobin OA, Ahmad S, et al. Serial development of pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Respiration 2008; 76:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/75\">",
"      Date H, Tanimoto Y, Goto K, et al. A new treatment strategy for advanced idiopathic interstitial pneumonia: living-donor lobar lung transplantation. Chest 2005; 128:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/76\">",
"      Miyoshi S, Schaefers HJ, Trulock EP, et al. Donor selection for single and double lung transplantation. Chest size matching and other factors influencing posttransplantation vital capacity. Chest 1990; 98:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/77\">",
"      Park SJ, Nguyen DQ, Savik K, et al. Pre-transplant corticosteroid use and outcome in lung transplantation. J Heart Lung Transplant 2001; 20:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/78\">",
"      Sch&auml;fers HJ, Wagner TO, Demertzis S, et al. Preoperative corticosteroids. A contraindication to lung transplantation? Chest 1992; 102:1522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/79\">",
"      McAnally KJ, Valentine VG, LaPlace SG, et al. Effect of pre-transplantation prednisone on survival after lung transplantation. J Heart Lung Transplant 2006; 25:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/80\">",
"      Stack BH, Choo-Kang YF, Heard BE. The prognosis of cryptogenic fibrosing alveolitis. Thorax 1972; 27:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/81\">",
"      Turner-Warwick M, Burrows B, Johnson A. Cryptogenic fibrosing alveolitis: response to corticosteroid treatment and its effect on survival. Thorax 1980; 35:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/82\">",
"      Turner-Warwick M, Burrows B, Johnson A. Cryptogenic fibrosing alveolitis: clinical features and their influence on survival. Thorax 1980; 35:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/83\">",
"      Costabel U, Matthys H. Different therapies and factors influencing response to therapy in idiopathic diffuse fibrosing alveolitis. Respiration 1981; 42:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/84\">",
"      Dayton CS, Schwartz DA, Helmers RA, et al. Outcome of subjects with idiopathic pulmonary fibrosis who fail corticosteroid therapy. Implications for further studies. Chest 1993; 103:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/85\">",
"      Douglas WW, Ryu JH, Bjoraker JA, et al. Colchicine versus prednisone as treatment of usual interstitial pneumonia. Mayo Clin Proc 1997; 72:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/86\">",
"      Douglas WW, Ryu JH, Swensen SJ, et al. Colchicine versus prednisone in the treatment of idiopathic pulmonary fibrosis. A randomized prospective study. Members of the Lung Study Group. Am J Respir Crit Care Med 1998; 158:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/87\">",
"      Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 183:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/88\">",
"      Collard HR, King TE Jr, Bartelson BB, et al. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003; 168:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/89\">",
"      Alakhras M, Decker PA, Nadrous HF, et al. Body mass index and mortality in patients with idiopathic pulmonary fibrosis. Chest 2007; 131:1448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/90\">",
"      Nadrous HF, Pellikka PA, Krowka MJ, et al. Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Chest 2005; 128:2393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/91\">",
"      du Bois RM, Weycker D, Albera C, et al. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 184:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/92\">",
"      Panos RJ, Mortenson RL, Niccoli SA, King TE Jr. Clinical deterioration in patients with idiopathic pulmonary fibrosis: causes and assessment. Am J Med 1990; 88:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/93\">",
"      Fern&aacute;ndez P&eacute;rez ER, Daniels CE, Schroeder DR, et al. Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: a population-based study. Chest 2010; 137:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/94\">",
"      Davies HR, Richeldi L. Idiopathic pulmonary fibrosis: current and future treatment options. Am J Respir Med 2002; 1:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/95\">",
"      Selman M, Thannickal VJ, Pardo A, et al. Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches. Drugs 2004; 64:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/96\">",
"      Tabata C, Tabata R, Kadokawa Y, et al. Thalidomide prevents bleomycin-induced pulmonary fibrosis in mice. J Immunol 2007; 179:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/97\">",
"      Horton MR, Santopietro V, Mathew L, et al. Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis: a randomized trial. Ann Intern Med 2012; 157:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/98\">",
"      Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 2011; 365:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/99\">",
"      Piguet PF, Vesin C. Treatment by human recombinant soluble TNF receptor of pulmonary fibrosis induced by bleomycin or silica in mice. Eur Respir J 1994; 7:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/100\">",
"      Giri SN, Hyde DM, Hollinger MA. Effect of antibody to transforming growth factor beta on bleomycin induced accumulation of lung collagen in mice. Thorax 1993; 48:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/101\">",
"      Piguet PF, Vesin C, Grau GE, Thompson RC. Interleukin 1 receptor antagonist (IL-1ra) prevents or cures pulmonary fibrosis elicited in mice by bleomycin or silica. Cytokine 1993; 5:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/102\">",
"      Piguet PF, Rosen H, Vesin C, Grau GE. Effective treatment of the pulmonary fibrosis elicited in mice by bleomycin or silica with anti-CD-11 antibodies. Am Rev Respir Dis 1993; 147:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/103\">",
"      Tobin RW, Pope CE 2nd, Pellegrini CA, et al. Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998; 158:1804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/104\">",
"      Raghu G, Freudenberger TD, Yang S, et al. High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis. Eur Respir J 2006; 27:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/105\">",
"      Sweet MP, Hoopes C, Golden J, et al. Prevalence of delayed gastric emptying and gastroesophageal reflux in patients with end-stage lung disease. Ann Thorac Surg 2006; 82:1570; author reply 1570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/106\">",
"      Schachter LM, Dixon J, Pierce RJ, O'Brien P. Severe gastroesophageal reflux is associated with reduced carbon monoxide diffusing capacity. Chest 2003; 123:1932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/107\">",
"      Lee JS, Collard HR, Raghu G, et al. Does chronic microaspiration cause idiopathic pulmonary fibrosis? Am J Med 2010; 123:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/108\">",
"      Pashinsky YY, Jaffin BW, Litle VR. Gastroesophageal reflux disease and idiopathic pulmonary fibrosis. Mt Sinai J Med 2009; 76:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/109\">",
"      Bandeira CD, Rubin AS, Cardoso PF, et al. Prevalence of gastroesophageal reflux disease in patients with idiopathic pulmonary fibrosis. J Bras Pneumol 2009; 35:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/110\">",
"      Raghu G, Yang ST, Spada C, et al. Sole treatment of acid gastroesophageal reflux in idiopathic pulmonary fibrosis: a case series. Chest 2006; 129:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/111\">",
"      Hershcovici T, Jha LK, Johnson T, et al. Systematic review: the relationship between interstitial lung diseases and gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2011; 34:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/112\">",
"      Sweet MP, Patti MG, Leard LE, et al. Gastroesophageal reflux in patients with idiopathic pulmonary fibrosis referred for lung transplantation. J Thorac Cardiovasc Surg 2007; 133:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/113\">",
"      Lee JS, Ryu JH, Elicker BM, et al. Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 184:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/114\">",
"      Collard HR, Anstrom KJ, Schwarz MI, Zisman DA. Sildenafil improves walk distance in idiopathic pulmonary fibrosis. Chest 2007; 131:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/115\">",
"      Jackson RM, Glassberg MK, Ramos CF, et al. Sildenafil therapy and exercise tolerance in idiopathic pulmonary fibrosis. Lung 2010; 188:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/116\">",
"      Idiopathic Pulmonary Fibrosis Clinical Research Network, Zisman DA, Schwarz M, et al. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med 2010; 363:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/117\">",
"      Hubbard RB, Smith C, Le Jeune I, et al. The association between idiopathic pulmonary fibrosis and vascular disease: a population-based study. Am J Respir Crit Care Med 2008; 178:1257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/118\">",
"      Sode BF, Dahl M, Nielsen SF, Nordestgaard BG. Venous thromboembolism and risk of idiopathic interstitial pneumonia: a nationwide study. Am J Respir Crit Care Med 2010; 181:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/119\">",
"      Kubo H, Nakayama K, Yanai M, et al. Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest 2005; 128:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/120\">",
"      Kinder BW, Collard HR, King TE Jr. Anticoagulant therapy and idiopathic pulmonary fibrosis. Chest 2006; 130:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/121\">",
"      Noth I, Anstrom KJ, Calvert SB, et al. A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012; 186:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/122\">",
"      Raghu G, Brown KK, Bradford WZ, et al. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 2004; 350:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/123\">",
"      Dubrawsky C, Dubravsky NB, Withers HR. The effect of colchicine on the accumulation of hydroxyproline and on lung compliance after irradiation. Radiat Res 1978; 73:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/124\">",
"      Zhang L, Zhu Y, Luo W, et al. The protective effect of colchicine on bleomycin-induced pulmonary fibrosis in rats. Chin Med Sci J 1992; 7:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/125\">",
"      Rennard SI, Bitterman PB, Ozaki T, et al. Colchicine suppresses the release of fibroblast growth factors from alveolar macrophages in vitro. The basis of a possible therapeutic approach ot the fibrotic disorders. Am Rev Respir Dis 1988; 137:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/126\">",
"      Douglas WW, Ryu JH, Schroeder DR. Idiopathic pulmonary fibrosis: Impact of oxygen and colchicine, prednisone, or no therapy on survival. Am J Respir Crit Care Med 2000; 161:1172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/127\">",
"      Selman M, Carrillo G, Salas J, et al. Colchicine, D-penicillamine, and prednisone in the treatment of idiopathic pulmonary fibrosis: a controlled clinical trial. Chest 1998; 114:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/128\">",
"      Kolb M, Kirschner J, Riedel W, et al. Cyclophosphamide pulse therapy in idiopathic pulmonary fibrosis. Eur Respir J 1998; 12:1409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/129\">",
"      Johnson MA, Kwan S, Snell NJ, et al. Randomised controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis. Thorax 1989; 44:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/130\">",
"      Baughman RP, Lower EE. Use of intermittent, intravenous cyclophosphamide for idiopathic pulmonary fibrosis. Chest 1992; 102:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/131\">",
"      Collard HR, Ryu JH, Douglas WW, et al. Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis. Chest 2004; 125:2169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/132\">",
"      Park SH, Saleh D, Giaid A, Michel RP. Increased endothelin-1 in bleomycin-induced pulmonary fibrosis and the effect of an endothelin receptor antagonist. Am J Respir Crit Care Med 1997; 156:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/133\">",
"      King TE Jr, Behr J, Brown KK, et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008; 177:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/134\">",
"      Raghu G, King TE Jr, Behr J, et al. Quality of life and dyspnoea in patients treated with bosentan for idiopathic pulmonary fibrosis (BUILD-1). Eur Respir J 2010; 35:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/135\">",
"      King TE Jr, Brown KK, Raghu G, et al. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 184:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/136\">",
"      Daniels CE, Lasky JA, Limper AH, et al. Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results. Am J Respir Crit Care Med 2010; 181:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/137\">",
"      Ziesche, R. Long-term survival in idiopathic pulmonary fibrosis patients treated with interferon gamma-1b (abstract). Chest 2002; 122:75S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/138\">",
"      Bienkowski RS, Gotkin MG. Control of collagen deposition in mammalian lung. Proc Soc Exp Biol Med 1995; 209:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/139\">",
"      Ziesche R, Hofbauer E, Wittmann K, et al. A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med 1999; 341:1264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/140\">",
"      King TE Jr, Albera C, Bradford WZ, et al. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet 2009; 374:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/141\">",
"      Pesci A, Bertorelli G, Manganelli P, Ambanelli U. Bronchoalveolar lavage analysis of interstitial lung disease in CREST syndrome. Clin Exp Rheumatol 1986; 4:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/142\">",
"      Lacher MJ. Spontaneous remission or response to methotrexate in sarcoidosis. Ann Intern Med 1968; 69:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/143\">",
"      Lower EE, Baughman RP. The use of low dose methotrexate in refractory sarcoidosis. Am J Med Sci 1990; 299:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/144\">",
"      Lower, EE, Baughman, RP, Winget, D. The long term use of methotrexate in patients with chronic symptomatic sarcoidosis. Sarcoidosis 1992; 9:465S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/145\">",
"      Scott DG, Bacon PA. Response to methotrexate in fibrosing alveolitis associated with connective tissue disease. Thorax 1980; 35:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/146\">",
"      Alton EW, Johnson M, Turner-Warwick M. Advanced cryptogenic fibrosing alveolitis: preliminary report on treatment with cyclosporin A. Respir Med 1989; 83:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/147\">",
"      Venuta F, Rendina EA, Ciriaco P, et al. Efficacy of cyclosporine to reduce steroids in patients with idiopathic pulmonary fibrosis before lung transplantation. J Heart Lung Transplant 1993; 12:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/148\">",
"      Moolman JA, Bardin PG, Rossouw DJ, Joubert JR. Cyclosporin as a treatment for interstitial lung disease of unknown aetiology. Thorax 1991; 46:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/149\">",
"      Grgic A, Lausberg H, Heinrich M, et al. Progression of fibrosis in usual interstitial pneumonia: serial evaluation of the native lung after single lung transplantation. Respiration 2008; 76:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/150\">",
"      Raghu G, Brown KK, Costabel U, et al. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am J Respir Crit Care Med 2008; 178:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/151\">",
"      Ward WF, Shih-Hoellwarth A, Tuttle RD. Collagen accumulation in irradiated rat lung: modification by D-penicillamine. Radiology 1983; 146:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/152\">",
"      Ekimoto H, Aikawa M, Ohnuki T, et al. Immunological involvement in pulmonary fibrosis induced by peplomycin. J Antibiot (Tokyo) 1985; 38:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/153\">",
"      Molteni A, Ward WF, Ts'ao CH, et al. Monocrotaline-induced pulmonary fibrosis in rats: amelioration by captopril and penicillamine. Proc Soc Exp Biol Med 1985; 180:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/154\">",
"      Geismar LS, Hennessey S, Reiser KM, Last JA. D-penicillamine prevents collagen accumulation in lungs of rats given bleomycin. Chest 1986; 89:153S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/155\">",
"      Steen VD, Owens GR, Redmond C, et al. The effect of D-penicillamine on pulmonary findings in systemic sclerosis. Arthritis Rheum 1985; 28:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/156\">",
"      de Clerck LS, Dequeker J, Francx L, Demedts M. D-penicillamine therapy and interstitial lung disease in scleroderma. A long-term followup study. Arthritis Rheum 1987; 30:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/157\">",
"      Cegla UH. [Treatment of idiopathic fibrosing alveolitis. Therapeutic experiences with azathioprine-prednisolone and D-penicillamine-prednisolone combination therapy]. Schweiz Med Wochenschr 1977; 107:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/60/34762/abstract/158\">",
"      Chapela R, Z&uacute;&ntilde;iga G, Selman M. D-penicillamine in the therapy of fibrotic lung diseases. Int J Clin Pharmacol Ther Toxicol 1986; 24:16.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4328 Version 23.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-79.122.249.114-3C057D9C1B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_60_34762=[""].join("\n");
var outline_f33_60_34762=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H48\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GENERAL APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Assessing disease severity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Choosing among therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Ongoing monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SUPPORTIVE CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Supplemental oxygen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Education",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Pulmonary rehabilitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      CLINICAL TRIALS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      N-ACETYLCYSTEINE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Dosage and administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2359278\">",
"      PREDNISONE-AZATHIOPRINE-N-ACETYLCYSTEINE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      PIRFENIDONE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H175732739\">",
"      Dosage and administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      ACUTE EXACERBATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Definition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Implications for practice",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Indications and choice of procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Physiologic changes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Prior treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      FUTURE DIRECTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4990318\">",
"      Thalidomide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28340207\">",
"      Tyrosine kinase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Immunomodulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Gastroesophageal reflux and chronic microaspiration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Phosphodiesterase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      OTHER AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H86165214\">",
"      Anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Colchicine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Cyclophosphamide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2359946\">",
"      Endothelin receptor antagonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      Imatinib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      Interferon gamma-1b",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      Methotrexate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      Cyclosporine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      Etanercept",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      Penicillamine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H48\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/4328\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4328|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?40/0/40972\" title=\"table 1\">",
"      Lung allocation score",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?40/23/41339\" title=\"table 2\">",
"      Complications of IPF or its Rx",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/40/41607?source=related_link\">",
"      Clinical presentation and diagnosis of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/40/16008?source=related_link\">",
"      General principles of the use of cyclophosphamide in rheumatic and renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/32/25098?source=related_link\">",
"      General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/23/4474?source=related_link\">",
"      Idiopathic interstitial pneumonias: Clinical manifestations and pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/14/42215?source=related_link\">",
"      Long-term supplemental oxygen therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/25/3480?source=related_link\">",
"      Lung transplantation: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/29/31192?source=related_link\">",
"      Lung transplantation: Disease-based choice of procedure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/20/26953?source=related_link\">",
"      Lung transplantation: General guidelines for recipient selection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11223?source=related_link\">",
"      Major side effects of low-dose methotrexate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/5/9306?source=related_link\">",
"      Methotrexate-induced lung injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/22/4456?source=related_link\">",
"      Overview of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/53/4952?source=related_link\">",
"      Overview of pulmonary function testing in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/39/32378?source=related_link\">",
"      Pathogenesis of idiopathic pulmonary fibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?7/31/7666?source=related_link\">",
"      Patient information: Idiopathic pulmonary fibrosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/12/21705?source=related_link\">",
"      Pneumococcal vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/56/27527?source=related_link\">",
"      Predictive scoring systems in the intensive care unit",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/31/16889?source=related_link\">",
"      Pulmonary hypertension associated with interstitial lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38840?source=related_link\">",
"      Pulmonary rehabilitation in COPD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/26/424?source=related_link\">",
"      Role of lung biopsy in the diagnosis of interstitial lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/8/37002?source=related_link\">",
"      Seasonal influenza vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/24/35210?source=related_link\">",
"      Treatment of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/26/32169?source=related_link\">",
"      Use of methotrexate in the treatment of rheumatoid arthritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_60_34763="Grading system predicting vascular invasion by pancreatic cancer";
var content_f33_60_34763=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F83537&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F83537&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Grading system* for predicting vascular invasion by a pancreatic cancer on dual-phase contrast-enhanced CT",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Category",
"       </td>",
"       <td class=\"subtitle1\">",
"        Description",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Grade 0",
"       </td>",
"       <td>",
"        No contiguity of tumor with a vessel",
"       </td>",
"       <td>",
"        Vascular invasion in 0 percent of cases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Grade 1",
"       </td>",
"       <td>",
"        Tumor contiguous with &lt;25 percent of the circumference of a vessel",
"       </td>",
"       <td>",
"        Vascular invasion in 0 percent of cases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Grade 2",
"       </td>",
"       <td>",
"        Tumor contiguous with 25 to 50 percent of the circumference of a vessel",
"       </td>",
"       <td>",
"        Vascular invasion in 57 percent of cases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Grade 3",
"       </td>",
"       <td>",
"        Tumor contiguous with 50 to 75 percent of the circumference of a vessel",
"       </td>",
"       <td>",
"        Vascular invasion in 88 percent of cases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Grade 4",
"       </td>",
"       <td>",
"        Tumor contiguous with &gt;75 percent of the circumference of a vessel or any vessel constriction",
"       </td>",
"       <td>",
"        Vascular invasion in all cases",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    * Proposed by Lu DSK, et al. AJR Am J Roentgenol 1997; 168:1439.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Wong JC, Raman S. Surgical resectability of pancreatic adenocarcinoma: CTA. Abdom Imaging 2010; 35:471. Copyright &copy; 2010; with kind permission from Springer Science + Business Media B.V.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_60_34763=[""].join("\n");
var outline_f33_60_34763=null;
var title_f33_60_34764="Dx asbestos disease A";
var content_f33_60_34764=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F61308&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F61308&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Criteria for diagnosis of nonmalignant lung disease related to asbestos",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            1986 Guidelines",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Chest film (irregular opacities)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pathology (College of American Pathologists)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Consistent time interval",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Occupational and environmental history",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Asbestos bodies or fibers",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            2004 Guidelines",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Evidence of structural change, as demonstrated by one or more of the following:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Imaging methods",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Histology (College of American Pathologists)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Evidence of plausible causation, as demonstrated by one or more of the following:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Occupational and environmental history of exposure (with plausible latency)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Markers of exposure (eg, plaques)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Recovery of asbestos bodies in lung tissue",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Comparison and notes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Demonstrates the existence of a structural lesion consistent with the effects of asbestos. The criteria outlined in the 1986 were most explicit for asbestosis.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Chest film, HRCT, and possibly future methods based on imaging. The 1986 guidelines specified ILO classification 1/1.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Criteria for identifying asbestosis on microscopic examination of tissue are unchanged.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Evidence of plausible causation implies that the temporal relationship, including latency, is plausible.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            The 2004 guidelines are not limited to lung tissue, consider the role of BAL to be established, and deemphasize fibers because they are difficult to detect and a systematic analysis for asbestos fibers is not generally available.",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Am J Respir Crit Care Med vol 170 pp 692, 2004; www.atsjournals.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_60_34764=[""].join("\n");
var outline_f33_60_34764=null;
var title_f33_60_34765="Fever and rash ddx by sign 1";
var content_f33_60_34765=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F78412&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F78412&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of fever and rash based upon accompanying signs",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Arthritis or arthralgia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Acute meningococcemia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Allergic purpura",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Disseminated gonococcal infection",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Erythema marginatum (acute rheumatic fever)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hepatitis B virus, prodromal phase",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lyme disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Parvovirus B19",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Reiter's syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Rocky Mountain spotted fever",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Roseola (especially in adults)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Rubella",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Serum sickness",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Still's disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Systemic lupus erythematosus",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Desquamation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Arcanobacterium haemolyticum infection",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Drug hypersensitivity",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Graft-versus-host reaction",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Kawasaki syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Measles",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Rocky Mountain spotted fever",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Scarlet fever",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Staphylococcal scalded-skin syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Stevens-Johnson syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Toxic epidermal necrolysis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Toxic shock syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            von Zumbusch pustular psoriasis",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Lymphadenopathy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Cervical",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Kawasaki syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Rubella",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Scarlet fever",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Generalized",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Infectious mononucleosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Secondary syphilis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Serum sickness",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Sarcoidosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Systemic lupus erythematosus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Toxoplasmosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Hilar",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Atypical measles",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Sarcoidosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Local",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Cat-scratch disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Tularemia",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Meningitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Acute meningococcemia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cryptococcosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Enterovirus (Coxsackieviruses, echoviruses)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Leptospirosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lyme disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Rocky Mountain spotted fever",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Secondary syphilis",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from Adapted with permission from Sanders, CV. Diagnosis of the patient with fever and rash. In: The Skin and Infection: A Color Atlas and Text, Sanders, CV, Nesbitt, LT (Eds), Williams &amp; Wilkins, Baltimore, 1995. With permission from Hurst, JW (Ed). Medicine for the Practicing Physician., 3rd ed, Butterworth-Heinemann, Boston, 1992, pp. 273- 274.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_60_34765=[""].join("\n");
var outline_f33_60_34765=null;
var title_f33_60_34766="Telangiectasia reticular veins and mild ankle edema";
var content_f33_60_34766=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F70438&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F70438&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Telangiectasia, reticular veins and mild ankle edema",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 235px; height: 299px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Reticular veins are dilated bluish subdermal veins, one to three millimeters in diameter. The deeper blue reticular veins contrast the bright red, fine telangiectasias. Mild ankle edema in this patient is evident at medial ankle below the malleolus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Patrick C Alguire, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_60_34766=[""].join("\n");
var outline_f33_60_34766=null;
var title_f33_60_34767="Hymenectomy";
var content_f33_60_34767=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F77857&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F77857&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 558px\">",
"   <div class=\"ttl\">",
"    Hymenectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 538px; height: 333px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_60_34767=[""].join("\n");
var outline_f33_60_34767=null;
